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Abstract 
Development of guanidine catalysts is explored through direct iminium chloride and 
amine coupling, alongside a 2-chloro-l,3-dimethyl-IH-imidazol-:-3-ium chloride (DMC) 
induced thiourea cyclization. Synthesized achiral catalyst N-(5H-
dibenzo[d,t][1,3]diazepin-6(7H)-ylidene)-3,5-bis(trifluoromethyl) aniline proved 
unsuccessful towards O-acyl migrations, however successfully catalyzed the vinylogous 
aldol reaction between dicbloro furanone and benzaldehyde. Incorporating chirality into 
the guanidine catalyst utilizing a (R)-phenylalaninol auxiliary, generating (R)-2-((5H-
dibenzo[ d,t] [1,3 ]diazepin-6(7H)-ylidene ) amino )-3 -phenylpropan-l-ol, demonstrated 
enantioselectivity for a variety of adducts. Highest enantiomeric excess (ee) was afforded 
between dibromofuranone and p-chlorobenzaldehyde, affording the syn conformation in 
96% ee and the anti in 54% ee, with an overall yield of30%. Attempts to increase 
asymmetric induction were focused on incorporation of axial chirality to the (R)-
phenylalaninol catalyst using binaphthyl diamine. Incorporation of (S)-binaphthyl 
exhibited destructive selectivity, whereas incorporation of (R)-binaphthyl demonstrated 
no effects on enantioselectivity. Current studies are being directed towards identifying the 
catalytic properties of asymmetric induction with further studies are being aimed towards 
increasing enantioselectivity by increasing backbone steric bulk. 
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I. Introduction 
1-1. Natural Products 
On a molecular level, our bodies reveal an array of chemical reactions responsible for 
maintaining health and integrity. Involved in these reactions is the innate ability of 
biological systems to distinguish the correct substrates for specific pathways. Not only 
must these substrates possess the correct functional groups for binding, but groups must 
be arranged in the correct regions, often requiring the correct asymmetry. Compounds 
without an internal plane of symmetry are referred to as asymmetric or chiral. They are 
enantiomers if they exist as non-superimposable mirror images of each other. These 
properties are exploited in metabolic processes, as demonstrated by the occurrence of 
asymmetric amino acids that primarily occur as the L-enantiomer in species such as 
mammals. Furthermore, these asymmetric compounds have important consequences to 
pharmaceutical industries. 
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Pharmaceuticals are often prepared from symmetric, achiral, chemical reagents incapable 
of distinguishing enantiomers, resulting in a mixture of products, termed a racemate. 
Most often only one of structures is correctly recognized by an active site, while the other 
enantiomer has two fates. It can either be harmless; eventually being degraded and 
making the drug 50% efficient, or it can react with different receptors causing undesired 
side effects. As a result, the biggest area of chemical research lies in asymmetric 
synthesis, referring to the stereoselective synthesis of chiral compounds. 
In relation to this work, focus is directed towards butenolide containing natural products, 
in addition to synthetic peptides, specifically with modifications at the a-carbon. 
1-1.1. Butenolides 
2 
Interest in butenolide compounds stems from the numerous butenolide containing natural 
products that have been identified. Butenolides are four carbon cyclic esters and fall into 
the class oflactones. They exhibit biological activities involving antibiotic37, antitumor40 
and cytotoxic properties.25 They also function as inhibitors ofbiosynthetic pathways.3! 
Interest lies in development of synthetic methods for facile construction of derivatives of 
butenolide natural products, such as tetronasin, Figure I-I .34 
Figure 1-1: Tetronasin, a butenolide (outlined in red) containing natural product. 
One group of derivatives is butenolides with substituents at the y-position, which refer to 
substitutions at the methylene position of the butenolide in Figure I-I . Such derivatives 
have previously been prepared through y-substitution of aryl aldehydes into butenolide 
derivatives, yielding y-alkenes, Scheme 1_1.3 
3 
CI 
0 Ar 0 1.TBOMSOTf 
CI R2VH CH2CI2, iPr2NEt, rt. 2hr N~O + • MeO .0 2.0BU, 5 hr 
R1 3. 3M HCI R1 
R2 OMe 
Scheme 1-1: y-Substitution of aryl aldehydes into butenollde derivatives 
Another potential approach, of more importance to this work, lies in the vinylogous aldol 
reaction, Scheme 1-2. It provides access to functionalized o-hydroxy carbonyl compounds 
containing a double bond. 6 
~ o 1. LOA, THF ROMe HMPA, -78°C J.-A 2. RCHO • LiO- b-{ o 
Scheme 1-2: Vinylogous aldol approach to 'Y-substituted butenolldes 
1-1.2. Modified Pep tides 
In addition to butenolides, there is also interest in generating modified a-amino acids, 
which play an important role in drug discovery and understanding biological 
phenomena.49 These amino acids possess modifications at the a-carbon, forming 
quaternary a-centers. This has the potential to introduce conformational constraints for 
optimal binding conformations, enhancing biological activity and potentially metabolic 
stability. As a result, the synthesis of a-substituted amino acids has attracted substantial 
attention. 49 
One potential method of achieving such derivatives is the O-acylated azalactone 
rearrangements. These have been reported using 4-( dimethylamino )pyridine (DMAP) and 
4-(pyrrolidino)pyridine (PPy), Scheme 1-3, generating new carbon-carbon bonding and 
quaternary centers. Since azalactones are more reactive, they provide selectivity that can 
be used towards preparation of a-alkylated amino acids. 46 
catalytic 
DMAPorPPY 
.. 
X=alkyl, OR 
Scheme 1-3: O-acylated azalactone rearrangement using DMAP or PPY 
Additionally, these rearrangements have also been accomplished using a chiral pyridine 
derivative, Figure 1_2.52 
Figure 1-2: Chiral pyridine derivative also used for O-acylated azalactone 
rearrangement 
1-2. Guanidines 
4 
In an approach towards synthesis of modified butenolide compounds, discussed in section 
1-1.1.1, and modified modified a-amino acids, section 1-1.1.2, this work utilizes 
guanidine catalysis towards achieving asymmetric product formation. The properties and 
chemistry ofthe guanidine moiety will be introduced next, with a brief overview of 
guanidine functionality in natural products and synthetic chemistry. 
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1-2.1. Guanidines - Properties and Chemistry 
The guanidine moiety presents itself in numerous naturally occurring products. It consists 
of a carbon bound to three nitrogen atoms. Guanidines can exist in three canonical forms, 
allowing for increased stabilization of their protonated guanidinium form, illustrated in 
Figure 1-3. As a result, they possess a high pKa, approximately 12.5, allowing them to act 
as superbases and remain protonated over a wide pH range, including those of 
physiological conditions.33 This leads to their characteristic function in biological 
activity, discussed below. 
Figure 1-3: Resonance structures of a guanidine moiety 
1-2.2. Guanidine Containing Natural Products 
Guanidines are prominent throughout nature and have been identified in many naturally 
occurring products. The most prominent of which is the amino acid L-arginine, Figure 
1-4. Arginine acts as an important substrate for living organisms, such as being an 
important metabolite that leads to the formation of creatine, which holds an important 
role in energy metabolism ofmusc1e and nerve tissues. 54 
NH 0 
H N)lN~··"Jl.OH 
2 H E 
NH2 
Figure 1-4: L-Arginine - guanidine containing amino acid 
6 
Guanidines are also found in more complex compounds, originating from terrestrial, 
marine and freshwater microorganisms, terrestrial and marine invertebrates, marine 
sponges and higher plants.4 They possess significant biological activity; displaying a 
variety of pharmacological properties including antifungal, antiviral and anti-H1V 
properties.4 Marine natural products have always been of significant interest. They 
possess biologically and pharmaceutically important substances and typically have 
chemically unique structures, rarely found in terrestrial metabolites.27 A classic example 
of such a product is ptilomycalin A, illustrated in Figure 1-5, from the Caribbean sponge 
Ptilocaulis spiculijer.26 This guanidine-containing substance was found to have 
significant cytotoxic activity against numerous cancer cell lines and against the DNA 
polymerase of Human immunodeficiency virus type 1 reverse transcriptase. 
Figure 1-5: Ptilomycalin A. 
Additionally, guanidines play an important part in structure and functionality of 
biological proteins and processes including enzymatic catalysis, further discussed below. 
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1-2.3. Guanidines in Enzyme Catalysis 
The aforementioned chemical properties of the guanidine moiety allows for the guanidine 
sidechain of arginine to hold various roles in enzymes. Guanidines remain protonated 
over a wide pH range, including those of physiological conditions, giving them an 
associated cationic character. Therefore, they are frequently found in enzymes whose 
ligands or cofactors contain anionic groups including nucleotide bases, phosphates and 
carboxylates,57 as seen in the active site of L-arginine: glycine amidinotransferase, Figure 
1_6.16 Within this active site, the protonated side chain of L-arginine residue, Arg322, 
coordinates to the carboxylate end of an L-arginine substrate.16 It heJps orientate and 
tether L-arginine for transfer of an amidino group to glycine, producing L-omithine and 
guanidinoacetic acid. 16 
Cy.407 -+ $er 
Figure 1-6: L-arginine 322 coordination of an L-arginine substrate.16 
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Guanidines are generally poor candidates for general bases in enzymatic catalysis 
because they typical exist in protonated states in physiological conditions. 14 However, 
arginine has been found to operate as a general base for the enzyme catalysts IMP 
dehydrogenase, fumarate reductase, pectate/pectin lyases and L-aspartate oxidase.14 This 
action is possible because these enzyme active sites possess residues that perturb the local 
pKa environments, allowing arginine to remain neutral, illustrated for pectate/pectin lyase 
. F' 7 14 ill 19ureI- . 
Figure 1-7: Arginine involved in pectate/pectin lyase.14 
As mentioned, guanidines play numerous roles in enzymatic catalysis, however, the 
basicity ofthe guanidine moiety is that which appeals most to chemists and leads to the 
growing interesting in development and utilization of novel guanidines as superbases in 
chemical catalysis. 
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1-2.4. Guanidines in Organic Synthesis 
Numerous nitrogen containing compounds are classified as organic bases; they include 
amines, amidines and guanidines. Of these, guanidines are the strongest bases because of 
the resonance stabilization oftheir conjugate acids, as depicted in Figure 1-3?O 
Additionally, in comparison to other organic bases, guandines provide easy access to a 
wide variety of molecular modifications; theoretically, five different chiralligands can be 
introduced to the nitrogen atoms, as illustrated in Figure 1-8. Hence, guanidines can play 
important roles in asymmetric catalysis. 
R=Possible Chiral Auxilaries 
Figure 1-8: Illustration ofpossihle locations for ligand incorporation on different nitrogen 
species. 
1-2.4.1. Preparation Methods/Synthesis 
The exploitation ofthe basic properties of guanidines has been limited due to difficulties 
in preparation of complex guanidine structures. 17 However, numerous preparation 
methods have recently been developed allowing for exploration of guanidine containing 
catalysts in synthetic chemistry. The various methods of guanidine preparation are 
discussed below. 
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1-2.4.1.1. Classic Preparation Method 
One ofthe first methods for the preparation of guanidines involves the reaction of 
thiourea with ammonia at elevated temperatures in the presence of lead (II) chloride.9 
Knowledge of such conversions led to the possibility of prepare various guanidines 
through simple transformations, as long as the thiourea derivatives were obtainable, as 
shown with work by Rao et aI., Scheme 1_4.42 However, despite offering complex 
guanidines, these methods were harsh and did not allow access to a variation of guanidine 
substituents. 
Scheme 1-4: a) Raney-Nickel, H2, EtOH, 70°C, 70 psi, 2 hr. b) HCI, Ether, rt, 2 hr. c) 
Triphosgene, pyridine, DCM, rt,4 hr. d) Lawesson's reagent, dioxane, reflux, 12 hr. d) 
NH~gS03CF3' DCM, -10°C -rt, 5hr. 
Eventually, guanidine preparation evolved into methods capable of generating complex 
guanidines, allowing for easy manipulation of N-substituents, helping tap into their 
unexplored potential in asymmetric catalysis. Synthesis of these more complex 
guanidines was achieved through various pathways, which will be briefly discussed. 
1-2.4.1.2. Synthesis of Cz Symmetric Guanidines 
The generation of C2 symmetric guanidine derivatives was achieved by Chinchilla et aI., 
as outline in Scheme 1-5.7 This involved the preparation of guanidines starting from 
thioureas, obtained by reacting two equivalents of a primary amine with carbon 
disulfide.7 Subsequent desulfurization of the thioureas was achieved using diisopropyl 
azodicarboxylate (DIAD) and triphenylphosphine, to afford homochiral carbodiimides, 
which were then reacted with a secondary amine, to yield C2 symmetric guanidines.7 
S 
2 R1NH2 + CS2 - )l 
R1HN NHR1 
DIAD 
TPP .. 
Scheme 1-5: Pathway for Cz-symmetric guanidine derivatives. 
1-2.4.1.3. Synthesis of Homochiral Guanidines 
A similar procedure for the synthesis of homochiral guanidines by the same authors is 
outlined in Scheme 1_6.7 Primary amines were reacted with isocyanates to afford the 
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corresponding ureas. Dehydration ofthe urea using bromotriphenylphosphonium bromide 
and triethylamine led to generation of carbodiimides, which were then reacted with 
secondary diamines, yielding the desired guanidines. 
Scheme 1-6: Generation of homochiral guanidines. 
1-2.4.1.4. Synthesis of Cyclic Guanidines 
The first method of preparing cyclic guanidines uses diamines as starting materials, as 
outlined in Scheme 1_7.17 The diamines are converted to ureas and then into their 
corresponding iminium chlorides, which are then coupled to various primary amines. 17 
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Additionally, this method is also viable for generation ofbicyclic compounds from cyclic 
diamine precursors, also shown in Scheme 1-7. 
X 
R1'NJeN'R1 (COCI)2 (-\L • 
L = H, Ph 
X=O,S 
Bicyclic 
Example 
Scheme 1-7: Cyclic guanidine formation through iminium chloride and amine coupling. 
The second method focuses on cyclic urea formation by cyclization of protected 
thioureas, derived from ethylene diamines, utilizing 2-chloro-I,3-dimethyl-4,5-dihydro-
IH-imidazol-3-ium chloride (DMC), Scheme 1_8.20 This method can utilize either 
trisubstituted or disubstituted thioureas to yield corresponding guanidines. 
1.DMC 
2. Deprotection 
• 
Scheme 1-8: Cyclic guanidine formation through thiourea cyclization. 
The third method involves transformation of simple guanidines into more complex 
structures. It again employs the use ofDMC induced cyc1ization, however this approach 
uses hydroxyethyl functionalized guanidines. Simple chlorination of the hydroxyl allows 
for subsequent cyclization and is shown in Scheme 1_9.20 This method is employed to 
introduce a cyclic nature to linear guanidines. Alternatively, it can be employed to 
introduce a bicyclic structure into pre-existing mono cyclic guanidines.20 
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DMC R1 N1R1 Et3N N~CI 
.. 
HN)lNH -solvent HN)lN 
RT I I I I R2 R2 R2 R2 
N~ DMC R1 N1R1 Et3N N~CI 
)l OH .. R2- N)lNH - R2- N)lN R2- N NH solvent 
l-\L reflux l-\L l-\L 
Scheme 1-9: Cyclization of guanidines with hydroxyethyl functionality. 
The development of numerous synthetic methods for generating chiral guanidines, 
discussed above, has expanded their uses as organic catalysts. 
1-2.4.2. Use as solution based Chiral Guanidine Catalysts 
1-2.4.2.1. Henry Reaction 
To date, guanidines play an important role in organic synthesis and have been used for 
catalysis of various enantioselective reactions, including the Henry reaction. 7 The Henry 
reaction is a classical carbon-carbon bond forming reaction between a nitro alkene and an 
aldehyde, discovered in 1895.41 The discovery of the strong ionic interaction formed 
between a bicyclic guanidine and nitroalkenes, illustrated in Figure 1-9, led to the 
identification of good potential models for asymmetric catalysts for the Henry reaction. 5 
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Figure 1-9: lon-pairing between a bicyclic guanidine and a nitroalkene. 
In 1994, the first asymmetric catalysis of the Henry reaction, utilizing a guanidine 
catalyst, was reported by Najera and coworkers.7 After investigation of several guanidine 
catalysts, the C2-symmetric catalyst shown in Scheme 1-10, achieved the highest 
enantioselectivity, affording products with an enantiomeric excess (ee) up to 54%.7 
+ 
Scheme 1-10: Henry reaction of aldehydes and nitro methane. 
Expanding on the Henry reaction, guanidines were explored for their potential as 
catalysts of diastereoselective reactions (d.r) between N,N-dibenzyl a-amino aldehydes 
and nitromethane, Scheme 1_11.36 
Bn 0 
Bn ..... N0H + CH3N02 
R 
Catalyst 1.10 
toluene, -20°C 
15 
Bn OH 
I ~ 
Bn ..... N~N02 
R 
Scheme 1-11: Diastereoselective Henry reaction of nitro methane with N,N-dibenzyl a-amino 
aldehydes. 
Catalyst 1.10, illustrated in Figure I-10, was similar to that used by Najera, however, it 
took advantage of more bulky substituents, affording ee's of92% in the best scenarios. 
Figure 1-10: Catalyst 1.10: 1,3-bis«R)-1-(naphthalen-1-yl)ethyl)guanidine. 
1-2.4.2.2. Michael Addition 
Further reviewing guanidine catalysts, there have been numerous reports of guanidine • 
catalyzed Michael additions.33 The Michael addition is a common approach to carbon-
carbon and carbon-halogen bond formation and involves the conjugate addition of a 
nucleophile to electron-deficient alkenes. 1 Michael reactions provide a good overview of 
the structurally different guanidine catalysts, spanning from linear, to cyclic, to 
polycyclic and to axial chiral. 
Ma and coworkers, employed a C2-symmetric linear catalyst, illustrated in Figure 1-11, 
similar to their catalyst for the Henry reaction (Scheme 1-10) for Michael addition of 
anthrone and N-methylmaleimide, Scheme 1_12.35,36 
16 
O~ H 2~ 1.11 .0 I .0 _ N 
~N)lN 
H H 
Figure 1-11: 1,3-bis«R)-1-phenylethyl)guanidine. 
No conclusive work has been performed to determine the reaction mechanism; however, 
product was obtained in 67% yield and 77% ee. 
catalyst 1.11 
+ • 
Scheme 1-12: Michael addition of anthrone and N-methylmaleimide. 
• Cyclic guanidines have also proven useful in Michael reactions. Ishikawa and coworkers, 
demonstrated the effectiveness of chiral guanidine catalysts in reactions of glycinate with 
various Michael acceptors.19 Their best catalysts, illustrated in Figure 1-12, afforded high 
yields with a highest ee of97%. 
1.12 
Figure 1-12: (S)-2-«( 4S,5S)-1,3-dimethyl-4,5-diphenyHmidazoHdin-2-ylidene)amino )-3-
phenylpropan-1-oL 
17 
Additionally, Ishikawa and coworkers found the same guanidine to successfully catalyze 
the reaction of2-cyc1openten-I-one and dibenzyl malonate, Scheme 1_13.32 However, the 
highest ee they obtained was 43%, with a yield of 65%. Despite this, they successfully 
demonstrated the potential of guanidine catalyst application towards an array of chemical 
transformations. 
o 
6 + o 0 Bno)!.JOBn 
o 
catalyst 1.12 
Scheme 1-13: Reaction of2-cyclopenten-l-one and dibenzyl malonate. 
Further expanding on the diversity of guanidine compounds, Tan and coworkers 
employed a bicyclic guanidine illustrated in Figure 1-13, and used it for the catalysis of2-
cydopenten-I-one with various 1,3 -dicarbonyl compounds, Scheme 1_14.58 They were • 
able to drastically improve on the results obtained by Ishikawa et aI., achieving excellent 
yields with most ees greater than 90%. 
;-N~ 1.13 
tBu-<,. J.... } ··'''tBu 
N"'-: N 
H 
Figure 1-13: Example ofa bicyclic guandine. 
o 
6 + catalyst 1.13 
Scheme 1-14: Catalysis of2-cyclopenten-l-one with various 1,3-dicarbonyl compounds. 
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The applicability of this bicyclic catalyst was also expanded to incorporated maleimides 
as Michael acceptors, Scheme 1_15.24 
catalyst 1.13 
• 
Scheme 1-15: Maleimide reactions with 1,3-dicarbonyl compounds. 
In addition to the previously discussed acyclic and cyclic guanidines, are guanidine 
catalysts possessing an axial chiral backbone. Axial chirality acts as an excellent 
approach to steering enantioselective reactions, demonstrated by Terada et aI., with their 
incorporation ofa binaphthyl backbone, Figure 1_14.47 
1.14a: Ar = 3,5-(3,5-di-tBuCsH3)2CsH3' R = Me 
~ R 1.14b: Ar = 3,5-di-tBuCsH3' R = Bn 
)=t.f 
N 
H 
Figure 1-14: Guanidine catalyst with axial chiral backbone.47 
Incorporation of axial chirality with attached 3,3'-aryl appendages, showed remarkable 
increases in selectivity towards Michael additions between dimethyl malonate and a 
variety of aromatic nitrokalkenes, Scheme 1-16. The reactions proceeded with high yields 
and enantioselectivities, with a highest yield of99% and 98% ee.47 
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Scheme 1-16: Michael additions between dimethyl malonate and nitroalkenes. 
However, as with every reaction, limitations were exhibited. Reaction ee's were greatly 
influenced by malonate bulkiness, with decreasing ee's coccuring as the steric bulk 
increased. Additionally, aromatic nitroalkenes were more reactive, while aliphatic 
derivatives required more catalyst and longer reaction times.47 Having described the roles 
of numerous guanidines in the evolution of enantioselective Michael additions, phospho 
and oxa- Michael reactions will now be addressed. 
1-2.4.2.3. Phospha-Michael Reaction 
Chiral a-amino and f3-amino phosphonic acids function as analogues to amino acids. 
Although numerous methods exist for the enantioselective preparation of a-amino 
phosphonic acids, not many exist for the f3 derivatives. 11 Tan et al. reported catalysis of 
the phospha-Michael reaction of conjugated aryl nitroalkenes with diaryl phosphine 
oxides, Scheme 1-17, using a chiral bicyc1ic guanidine, Figure 1-15. Excellent 
enantioselectivities, enhanced by recrystallization, were obtained with di-(1-naphthyl) 
phosphine o.xide and various nitroalkenes using 10 mol % catalyst loading. ll 
+ 
Scheme 1-17: Reaction of conjugated aryl nitroalkenes with diaryl phosphine oxides. 
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;-N-"\. 1.15 
tBu-\. J-. }'"lItBu 
N~ ~ 
Figure 1-15: Chiral bicyclic guanidine. ll 
Looking at a related phospha-Michael reaction, the potential for variability in guanidine 
catalysts of similar reactions is clearly demonstrated. The catalysts illustrated in Figure 
1-14 and Figure 1-15, are remarkably different, yet they catalyze closely related reactions, 
seen by comparing Scheme 1-17 to Scheme 1-18. Additionally, this demonstrates that use 
of an axial chiral guanidine shows improvement in enantioselectivities, with a best result 
being 97%.48 
OPh 
+ 
catalyst 1.16 I O=P-OPh 
R1~N02 tBuOMe, -40°C 
Scheme 1-18: Catalysis of diphenyl phosphite to nitroalkenes. 
1-2.4.2.4. Oxa-Michael Reactions 
To further demonstrate the applicability of guanidine catalysts, oxa-Michael reactions are 
addressed. They can be used in the formation of oxygen containing heterocycles, forming 
chromanes and flavanes, present in numerous natural products, such as vitamin E. 44 
Ishikawa et al. recently explored the potential of intramolecular oxa-Michael cyclizations 
of phenol derivatives as an entry to chiral chromanes, Scheme 1-19.44 Using a chiral 
guanidine catalyst, depicted in Figure 1-16, they were able to obtain enantioselectivities 
of 76% with yield of 83 %. 44 These results demonstrate the effectiveness of guanidine 
catalysts in this field. 
Catalyst 1.17 
(20 mol %) C()<C02Me 
--------... I ,) 
,.,.::; .-CHCI3 0 
Scheme 1-19: Oxa-Michael cyclizations of phenol derivatives. 
/Ph 1.17 
N~OH 
Me-N)lN-Me ditS 
Figure 1-16: Chiral guanidine catalyst for Scheme 1-19. 
1-2.4.2.5. [4+2] Cycloadditions 
Guanidines have also been employed as catalysts for enantioselective [4+2] 
cycloadditions, also known as Diels-Alder reactions. However, as opposed to more the 
commonly explored Lewis acid catalyzed cycloadditions, guanidines are involved in 
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asymmetric base catalyzed Diels-Alder reactions. These guanidines, an example of which 
is illustrated in Figure 1-17, function as Bnmsted bases activating dienes to give higher 
HOMO energies, opposed to lowering LUMO energies of the dieneophile in Lewis acid 
activation. For example, guanidines have been shown to catalyze the Diels-Alder reaction 
of anthrone with activated oletins, outlined in Scheme 1-20, with many examples 
exhibiting high yields and ees greater than 98%.45 
1.18 
Figure 1-17: Bronsted base guanidine catalyst for Diels-Alder reactions. 
+ 
catalyst 1.18 
(10 mol%) 
OCM, -20°C 
6hr 
Scheme 1-20: Diels-Alder reaction of anthrone with activated olefins. 
1-2.4.2.6. Nucleophilic Epoxidation Reaction 
Chiral guanidines have also been investigated as chiral catalysts for nucleophilic 
epoxidation reaction. 12 Cyclic guanidines, illustrated in Figure 1 -18a, used in 
stoichiometric amounts were found to give respectable results, however, utilizing 
guanidinium salts, illustrated in Figure 1 -18b, provided better yields and 
enantioselectivities (99%, 93% respectively) for chalcone epoxidations, Scheme 1_21.15 
rN"'l 19~BF~~J;; 
H00N.J-..N)··"I/OH very 
H + 
1.19a 1.19b 
Figure 1-18: a) Cyclic guanidine for epoxidations. b) Guanidinium salt for epoxidations. 
22 
o 
Ph~Ph 
catalyst 1.19a 
(5 mol %), aq. NaOCI 
Toluene, 16hr, O°C to rt 
o 
~ Ph ()"". Ph 
Scheme 1-21: Chalcone epoxidations using catalysts in Figure 1-18. 
1-2.4.2.7. Electrophilic Amination Reactions 
23 
Further investigating the use of guanidine catalysts, axially chiral guanidine illustrated in 
Figure 1-19, functioned well as catalysts for asymmetric electrophilic aminations. 
Reactions were performed with 1,3-dicarbonyl compounds using di-tert-butyl 
azodicarboxylate, outlined in Scheme 1-22, whose bulkiness was crucial for 
enantioselectivity. Reactions were carried out affording excellent ees.47 
1.20: Ar = 4-(3,5-di-tBuC6H3)C6H4 
Figure 1-19: Axial chiral guanidine for electrophilic amination. 
Boc, 
N 
II N, 
Boc 
catalyst 1.20 
(2 mol %) 
• 
Scheme 1-22: Amination of 1,3-dicarbonyl compounds with di-tert-butyl azodicarboxylate. 
1-2.4.2.8. Mannich Reactions 
Guanidines have also been shown to act as catalysts for Mannich reactions, a reaction 
used for converting imines to chiral p-amino carbonyls.53 Previously mentioned 
24 
guanidine 1.12, illustrated in Figure 1-12, was shown to also catalyze the Mannich 
reaction of N-Boc protected imines to a,p-diamino esters, outlined in Scheme 1-23?8 
These reactions help demonstrate the flexibility of guanidine catalysts towards a variety 
of reactions. 
Boc 
N' 
~H + 
catalyst 1.12 
(10 mol %) 
-45°C, toluene 
Scheme 1-23: ManDich reaction of N-Boc protected imines to a,p-diamino esters. 
1-2.4.2.9. Strecker Reaction 
Another classic reaction for which guanidines have been employed to attain high 
enantioselective reactions is the Strecker reaction, shown in Scheme 1-24. First reported 
in 1850, it is an excellent method for the synthesis of a-amino acids. 13 Lipton et at, 
reported a cyclic dipeptide guanidine catalyst, illustrated in Figure 1-20, to afford good to 
excellent enantioselectivities with N-benzhydryl imines.23 
Figure 1-20: Cyclic dipeptide guanidine catalyst. 
+ HeN 
catalyst 1.21 
(2 mol %) 
Scheme 1-24: Synthesis of a-amino acids with N-benzhydryl imines. 
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Moreover, Coreyet aI., applied a bicyclic guanidine 1.21, illustrated in Figure 1-21, to the 
Strecker synthesis, showing improvements over the dipeptide catalyst in reactions of 
aliphatic imines.8 
Ph-r:~)""'Ph 1.22 
N~N 
H 
Figure 1-21: Bicydic guanidine used for strecker synthesis. 
1-2.4.2.10. Reduction Reactions 
Continuing the investigation of guanidine catalyzed reactions, Basavaiah et aI, reported 
chiral guanidines, illustrated in Figure 1-22, showing enantioselective catalysis ofborane 
mediated reductions, such as thoseofphenacyl bromide, outlined in Scheme 1-25.2 The 
reaction yielded greater enantioselectivity under refluxing conditions then room 
temperature, with increases seen from 37% to 83%.2 
NH 1.23 
a.:;N-Ph 
Figure 1-22: Guandine catalyst for borane reductions. 
o 
Ph~Br 
+ 
catalyst 1.23 OH 
(15 mol %) , 
.. Ph~Br 
toluene, reflux 
Scheme 1-25: Catalysis ofborane mediated reduction of ph en acyl bromide. 
1-2.4.2.11. Vinylogous Aldol Reactions 
26 
The vinylogous aldol reaction is a classic carbon-carbon bond forming reaction providing 
hydroxyl functionalized compounds containing a double bond, Scheme 1-26. One ofthe 
most recently reported guanidine catalyzed asymmetric reactions is the vinylogous aldol 
reaction.51 Ube et al. reported good yields with diastereotopic selection favouring syn 
over anti conformations, (90: 10) with an enantiomeric excess of 99% with their best 
catalyst 1.24h, illustrated in Figure 1-23. 
x~ + 
X 
RCHO 
Catalyst 1.24h 
(5 mol %) 
.. 
Scheme 1-26: Vinylogous aldol reaction of aldehydes with butenolide. 
H 
N G FN 
N 
H 
1.24a: Ar = Ph, G = CH3 
1.24b: Ar = Ph, G = PH2CH 
1.24c: Ar = 3,5-tBu2CaH3,Ph, G = PH2CH 
1.24d: Ar = Ph, G = (3,5-Me2CaH3)2CH 
1.24e: Ar = Ph, G = (3,5-(CF3hCaH3hCH 
1.24f: Ar = Ph, G = (4-MeOCaH4hCH 
1.24g: Ar = Ph, G = (3,5-(MeOhCaH3hCH 
1.24h: Ar = Ph, G = (3,4,5-(MeOhCaH2hCH 
Figure 1-23: Axial chiral guanidine catalyst for Vinylogous Aldol reactions. 
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1-2.4.3. Solid Phase Chiral Guanidine Catalysts 
Opposed to classic solution based organic catalyst, solid phase reagents offer various 
advantages, including easier scale-up operations and reusability. The use of chiral 
guanidines in this field is limited; however, Ishikawa et al. have synthesized a polymeric 
form of a previous solution based catalyst. 32 
1.25a 1.25b 
Figure 1-24: a) Free Form Catalyst. b) Immobilized Polymeric Guanidine. 
Scheme 1-27: Michael Reaction of Glycinate. 
The solution based catalyst 1.25a, Figure 1-24, afforded 74% ee ofthe Michael reaction 
product of glycinate, Scheme 1-27 ,however, despite their structural similarities; the 
polymeric guanidine, Figure 1-24b, only afforded the product in moderate yields, with 
lower ee's of 45%.32 The inactivity of such guanidines is most likely a result of the 
inaccessibility ofthe embedded catalyst, and more work needs to be done for 
development of efficient solid phase guanidine catalysts. 32 
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1-2.4.4. Coordination by Chiral Guandine Ligands 
In addition to solid phase, chiral guanidines are being utilized in other synthetic 
applications, such as metal ligands. Guanidine coordination has proven successful with 
metals such as zinc(II), illustrated in Figure 1-25 and molybdenum.29 Preliminary work 
has been focused towards the previously described Henry reaction, illustrated in Scheme 
1-10. However, despite showing successful catalysis, enantioselectivity was negligible.29 
Figure 1-25: Guanidine coordination to zinc. 
The use of guanidine catalysts to numerous synthetic reactions, as shown above, 
demonstrates their impact and future potential towards synthetic chemistry. The 
application ofthese catalysts in natural product synthesis is promising as they allow for 
greener chemistry, avoiding metal catalysis and harsh reaction conditions. 
1-3. Focus 
The focus of this work involves exploration of different synthetic routes for preparing 
polycyclic guanidine catalysts, possessing a 7-membered guanidine ring and an aromatic 
backbone. Focus will then shift towards utilization of synthesized guanidine catalysts for 
generating modified butenolide compounds and a-amino acids, helping provide entry into 
new routes for development of natural products composed of such derivatives. 
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1-3.1. Catalyst Synthesis 
Two synthetic routes will be mainly explored for the generation of such catalysts. The 
ftrst will focus on generation of iminium chlorides from urea or thiourea precursors, and 
subsequent reactions with primary amines to afford the desired guanidines, Scheme 1-28. 
This scheme shows promise for efficient access to a multitude of catalysts with varying 
auxiliaries. 
(COClh 
solvent 
Scheme 1-28 : Guanidine generation through chloroiminium and amine coupling 
The second potential method for guanidine synthesis is based on the formulation of 
thioureas, through reactions with isothiocyanates and diamines, followed by their 
subsequent cyc1ization to yield corresponding guanidines, outlined in Scheme 1-29. 
CI 
R1 R1 S Me"'N~N-Me R1 R~~NH2 R-NCS R~~N)lN'R 'L..J R~~NH R .. H H .. FN' 
R3 NH2 OCM R3 NH2 NEt3. MeCN. reflux R3 NH 
R. ~ R. 
Scheme 1-29 : Guanidine formation through thiourea addition and DMC induced 
cyclization. 
Upon successful generation of such guanidine species, their potential for catalysis and 
furthermore, asymmetric induction of reactions applicable to the synthesis of desired 
30 
natural products will be assessed and explored. In particular, reactions pertaining to 
synthesis ofbutenolide units and synthetic peptides are of interest. 
1-3.2. Guandine utilization towards 'Y-substituted butenolide derivatives 
In relation to butenolide derivatives, this work focuses mainly on y-substituted 
butenolides and the generation of enantioselective derivatives through direct vinylogous 
aldol reactions. To date, there are very limited enantioselective reports of direct 
vinylogous aldol reactions, giving much appeal to this area. To allow entry into this field, 
use of2-furanone derivatives as vinylogous nucleophiles will be utilized, as they are the 
simplest forms of but enol ide compounds. 
Moreover, dihalofuran-2(5H)-ones will be utilized, Scheme 1-30. Interest in these 
particular furanones exists because halo substituents enhance the acidity at of the y 
• positioned hydrogens, allowing greater reactivity. At the same time, halo substituents also 
block the a-postion from bond formation. 51 
+ 
o }-H 
R 
cat x~ 
X 
Scheme 1-30: Vinylogous aldol reaction utilizing dihalofuran-2(5H)-ones. 
1-3.3. Modified a-Amino acid synthesis through O-acyl migrations 
Lastly, interest lies in generation of modified a-amino acids through O-acyl migrations. 
This method possesses tremendous potential towards stereoselective preparation of a-
alkylated amino acids. Additionally, interest also lies in the area because current 
reactions, described in section 1-1.1.2, utilize nitrogen base catalysts, sparking the 
exploration of guanidine use in this field. Work will focus on attempting O-acyl 
migrations using synthesized guanidines, outlined in Scheme 1-31. 
Guanidine 
catalyst 
X=alkyl, OR 
Scheme 1-31: O-acyl migration 
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II. Results and Discussion 
II-I. Synthesis of Guanidine Catalysts 
11-1.1. Approaches Utilizing Iminium Chloride and Amine Coupling 
Work towards the synthesis of chiral guanidine catalysts began with the reaction of 
iminium chlorides with primary amines, as described in Scheme 1-28. As noted, the 
successful implementation ofthis route has great potential for the efficient synthesis of 
numerous guanidines possessing various auxiliaries, that sharing a similar backbone 
structure. 
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Investigation of this reaction began with the generation ofa simple achiral guanidine. N-
(5,7-dimethyl-5H-dibenzo[d,f][1,3]diazepin-6(7H)-ylidene)-I-phenylmethanamine. 7 was 
prepared from 2,2'-diaminobiphenyl, 1, and benzyl amine, 2, in 4 steps, as outlined in 
Scheme II -1. The initial step invo Ived the transformation of 2,2' -diamino biphenyl into its 
• 
corresponding urea 3, using the methodology ofNiementowski.39 Formation of the urea 
introduced the required carbon linkage seen between the free amines of the guanidine 
product. The goal was now to substitute the carbonyl with an amine species. However, 
prior to the amination, activation ofthe urea carbonyl was required. To accomplish this, 3 
was N-methylated using methyl iodide. This helped prevent formation of stable resonance 
species and helped protect the N-positions in successive reactions. Alkylation ofthese 
positions using other species is discussed below, Scheme 11-3. Following alkylation, 4, 
was converted into the highly reactive 6-chloro-5,7-dimethyl-5H-
dibenzo[d,f][1,3]diazepin-7-ium chloride, 5, by chlorination using oxalyl chloride, 
fo llowing procedures s~milar to those previously reported by Ishikawa et a!. 17 
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Chlorination was found to be most successful in the absence of solvent and excess oxalyl 
chloride. The iminium chloride species was then aminated with achiral benzyl amine, 6, 
affording the desired product, 7. 
AcOH 8=NH NaH, Mel • /=0 • 
reflux,3h ~ I NH DMF 
::::,... 
1 2 3 
70% yield 
8=' 
Q N /=0 
~ I N" 
::::,... 
4 
95% yield 
(COCI)2 
• 
reflux 
~~ / ---.1\ Q N/=N~ ~ I N ::::,... \ 7 
76% yield 
Scheme IT-I: Synthetic towards access to guanidines using iminium chlorides. 
Generation of achiral guanidine 7 demonstrated the ease with which various auxiliaries 
could be integrated into the synthetic approach that allowed for the preparation of chiral 
guanidines. At that stage, work was directed towards the development oftwo novel chiral 
guanidine catalysts, 8 and 9, each possessing the optically active (R)-phenylalaninol 
auxiliary, which has shown to possess good enantioselective induction in other 
works.19,44,51 In addition to exploring the effect of a phenylalaninol auxiliary, the effects 
of utilizing bulky nitrogen substituents, such as N-protecting groups, on asymmetric 
catalysis was also investigated. 
34 
8 9 
Figure 11-1: (R)-phenylalaninol guandine catalysts with varying N-protecting groups 
The frrst attempt at synthesis of(R)-2-«5,7-dimethyl-5H-dibenzo[d,f][1,3]diazepin-
6(7H)-ylidene)amino)-3-phenylpropan-l-01, 8, was performed, Scheme 11-2, through an 
amination of the iminium chloride species, 5, generated using Scheme 11-1, with 
phenylalaninol. However, numerous attempts at product isolation and identification, 
using extractions and chromatography, proved unsuccessful. This was most likely 
attributed to the polar properties ofthe hydroxyl functionality, resulting in difficulties in . 
isolation. Therefore, in an attempt to increase the ease ofproduct isolation, we protected 
the hydroxyl functional group of the (R)-phenylalaninol with tert-butyldimethylsilyl 
(TBDMS), thereby reducing its hydrogen bonding character and possibly averting 
possible side reaction. Unfortunately, difficulties in product isolation after amination with 
TBDMS protected (D)-phenylalaninol were still encountered. More investigation into this 
reaction is warranted. In tandem with this work, generation of guanidine catalyst 9 was 
also being explored. 
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5 8 
Scheme 11-2: Chloroiminium coupling with protected and unprotected (R)-phenylananinoL 
Recent work using imidazolidine rings found that the incorporation of bulky substituents 
has positive effects on asymmetric induction and additionally, increases the rate of 
catalytic turnover.43 Therefore, alongside the aforementioned work, attempts to 
synthesize (R)-2-« 5, 7-dibenzyl-5H-dibenzo[ d,f][1 ,3]diazepin-6(7H)-ylidene ) amino )-3-
phenylpropan-l-ol,9, were made, Scheme 11-3. The synthetic pathway follows that of 
Scheme II-I, with a few modifications. First, in place of N-methyl substituents, benzyl 
groups were incorporated. N-benzylation of5H-dibenzo[d,f][1,3]diazepin-6(7H)-one was 
accomplished using benzyl bromide, affording 5,7-dibenzyl-5H-
dibenzo[d,f][1,3]diazepin-6(7H)-one, 10, according to the literature procedure by 
Kostyanovsky.30 Additionally, conversion into the corresponding iminium chloride 12 
failed with oxalyl chloride. This was a result ofthe unreactive nature of benzyl 
substituted ureas, as reported by Ishikawa et al. 43 In order to increase reactivity of the 
urea, 10 was converted into the corresponding thiourea, 11, using Lawesson's reagent, 
following a procedure reported by Ishikawa et al. 43 Substitution ofthe urea oxygen, with 
the larger, more reactive sulfur atom successfully allowed for direct chlorination 
previously employed using oxalyl chloride. Unfortunately, attempts at amination with 
(R)-phenylalaninol presented the same problems previously encountered with the N-
36 
methylated species. After numerous attempts at isolation through chromatographic 
methods and reported extractions on similar compounds,19 other preparation methods of 
this guanidine were explored. 
8='H 
8 Lawessan's Reagent 
~ N KOH,D~ ~ a-xylene, 145°C,24hr (COCI)2 FO u B: :80 • FS • ~ I N, ~ I N ::::,.. H ~o 
3 ~ # 
10 11 
65% yield 91% yield 
Scheme 11-3: Preparation ofN-benzyl substituted urea's and coupling with (R)-
Phenylalaninol. 
11-1.2. Approaches Utilizing DMC-Induced Thiourea Cyclization 
8 ct 
8=w }-CI ~ I N ~o 
12 
50% yield 
Et3, 
H2CI2, 
rt,24hr 
With failures in guanidine formation utilizing the previous methods described up to this 
point, our efforts focused next on guanidine preparation utilizing DMC-induced thiourea 
cyclization, Scheme 1-29. This work began with the preparation ofthe 7-membered 
guanidine, initially possessing an achiral backbone. 
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In this vein, targeted N-( 5H -dibenzo[ d,t] [1,3 ]diazepin-6(7H)-ylidene )-3,5-
bis(trifluoromethyl)aniline, 19, was prepared via the four step synthesis, as outlined in 
Scheme 11-4. The synthesis began with the mono acylation of [1,1'-biphenyl]-2,2'-
diamine, 1, following a protocol established by Wang and coworkers, which afforded the 
protected acetamide species 14.55 To prevent formation ofa bisacylated species, it was 
necessary to carry out the reaction under acidic reaction conditions, reducing the 
nucleophilic nature ofthe binaphthyl amines and making mono-acylation more 
favourable. Additionally, using 1 molar equivalent of acetic anhydride resulted in small 
amounts ofbisacylation, therefore, an equivalence of 0.95 was used. The resulting 
monoacylated biphenyl species N-(2'-amino-[1,1 '-biphenyl]-2-yl)acetamide, 14, was 
converted into a biphenylamine thiourea (N-(2'-(3-(3,5-bis(trifluoromethyl)phenyl) 
thioureido )-[ 1, 1 '-biphenyl] -2-yl)acetamide), 16, with 1-isothiocyanato-3 ,5-
bis(trifluoromethyl)benzene, 15, using methodology by Wang and coworkers!. 
Afterwards, a protocol by Ishikawa and coworkers was used to generate the thiourea 
derivative 18 by using 2-chloro-1 ,3-dimethylimidazolinium chloride (DMC), 17. DMC 
induced cyclization ofthe acetamide nitrogen with the thiocarbonyl, thereby forming the 
imidazo lidine ring system of reaction product 1-(6-( (3,5-bis( trifluoromethyl)phenyl) 
imino )-6,7 -dihydro-5H-dibenzo[ d,t] [1,3 ]diazepin-5-yl)ethanone. Lastly, the acyl 
protecting group was removed by treatment with base reducing the acetamide back to its 
native form, giving the fmal product, N-(5H-dibenzo[d,t][1,3]diazepin-6(7H)-ylidene)-
3,5-bis(trifluoromethyl)aniline, 19. 
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Scheme 11-4: Synthetic route ofthe four step DMC-induced guandine formation. 
Upon successful utilization of this route towards guanidine preparation, a test synthesis 
was conducted utilizing (S)-(-)-1,1'-binaphthyl-2,2'-diamine, 20, checking the ability to 
incorporate axial chirality using the protocol outlined in Scheme 11-4. Catalyst 
preparation was successful for preparing 21 from 20. More attention to this axial chiral 
concept is given later in this work. 
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Scheme 11-5: Generation of a guanidine catalyst with axial chirality. 
Additionally, following successful implementation of a protocol for guanidine 
preparation, focus was directed towards the implementation of desired chiral auxiliaries, 
such as (R)-phenylalaninol, through generation of corresponding isothiocynates. Use of 
this methodology, alongside small modifications, led to the successful generation of our 
desired guanidine (R)-2-((5H-dibenzo[d,f][I ,3]diazepin-6(7H)-ylidene)amino)-3-
phenylpropan-l -ol, 29. In comparison to the previous route, mono acylation ofthe 
diamine starting material was not required. Overall, 29 was prepared from (R)-
phenylalanine and 2,2'-diaminobiphenyl through a seven-step process, shown in Scheme 
11-6. 
The preparation of29 began with the synthesis of optically active, TBDMS protected (R)-
phenylalaninol isothiocynate, 26, which was prepared from its corresponding amino acid, 
(R)-phenylalanine, 22, via 4 steps. Following a synthetic route by Brenna et aI., the 
carboxylic acid was reduced using NaBH4 and h treatment,59 forming (R)-phenylalaninol, 
23, followed by protection of the free hydroxyl group with TBDMSCI, yielding 24. 
Following methodology by Ishikawa et aI., 24 was treated with carbon disulfide and 
triethylamine, forming triethylammonium dithiocarbamate 25, which underwent a 
dehydrosulfide reaction using DMC induction, affording (R)-tert-butyl(2-isothiocyanato-
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3-phenylpropoxy)dimethylsilane, 26.21 (Iso be, 1999) Upon isothiocyanate formation, 26 
was treated with unprotected 2,2' -diaminobiphenyl, affording the desired thiourea 
derivative (R)-1-(2'-amino-[1, 1 '-biphenyl]-2-yl)-3-(1-«tert-butyldimethylsilyl)oxy)-3-
phenylpropan-2-yl)thiourea, 27. NMR analysis of 27 in CDCh and DMSO identified the 
existence of multiple rotomeric states. The free rotation of the thiourea, alongside its 
bulky substituents, prevented dithiourea formation with the second available amine, 
eliminating the need for mono acylation mentioned earlier. This was favourable as it 
eliminated two steps from the synthetic pathway. Compound 27 was then converted to 
the corresponding guanidine derivative (R)-1-«tert-butyldimethylsilyl)oxy)-N-(5H-
dibenzo[d,f][1,3]diazepin-6(7H)-ylidene)-3-phenylpropan-2-amine 28, through DMC-
induced cyc1ization, as described earlier.22 This derivative affords access to two potential 
pathways. The first, involves simple deprotection ofthe hydroxyl group using TBAF, 
affording (R)-2-«5H-dibenzo[ d,f][l ,3]diazepin-6(7H)-ylidene ) amino )-3-phenylpropan-l-
01,29. This N-protonated guanidine will be scanned for its potential towards asymmetric 
catalysis of desired reactions. Additionally, a second pathway which can be explored 
involves further modification of the guanidine species through N-alkylation. This has the 
potential to provide access to more complex guanidines, such as 8 and 9, which were 
unattainable through methods previously discussed. 
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Scheme 11-6: Preparation of (R)-2-«SH-dibenzo[d,t] [1,3]diazepin-6(7H)-ylidene)amino )-3-
phenylpropan-l-ol. 
11-1.3. Synthesis of Guanidines with Axial Chirality 
After successfully generating the guanidine catalyst with the (R)-phenylalaninol 
auxiliary, interest shifted towards the application ofthis catalyst in natural product 
synthesis, discussed in Section 1-3. Alongside this work, interest developed towards 
incorporation of additional chiral functionality, such as axial chirality, discussed in 
Section 11-2.2. These catalysts were prepared using methods employed in Scheme 11-6, 
catalysts with both (S)-(-)-1,1'-Binaphthyl-2,2'-diamine, Scheme 11-7, and (R)-(+)-l,l'-
Binaphthyl-2,2'-diamine, Scheme 11-8. 
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Scheme 11-7: Truncated scheme of phenyl ala nino I guanidine synthesis from (S)-(-)-l,l'-
Binaphthyl-2,2' -diamine 
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Scheme 11-8: Truncated scheme of phenyl ala nino I guanidine synthesis from (R)-(+)-l,l '-
Binaphthyl-2,2'-diamioe 
11-2. Enantioselective Catalysis 
The synthesized guanidines we prepared were tested for their efficacy for catalysis of 
desired reactions. Achiral guanidine catalyst N-(5H-dibenzo[d,f][1,3]diazepin-6(7H)-
ylidene)-3,5-bis(trifluoromethyl)aniline, 19, was first used as an reference for accessing 
the potential of the accessing the desired 7 membered ring guanidine structure. 
11-2.1. O-Acylated Azalactone Rearrangement. 
The catalytic potential of 19 for O-acylated azalactone rearrangements primarily 
assessed. This reaction that can be used for entry into synthesis of a-alkylated amino 
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acids, discussed in Section 1-1.2. Specifically, work focused on intermolecular O-acyl 
transfer of benzyl carbonate, 36, prepared according to the literature, as outline in 
Scheme 11_9. 10 Generation of the final product and all intermediates were confirmed by 
NMR comparison to literature fmdings. 
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Scheme 11-9: Preparation of 4-benzyl-2-(4-methoxyphenyl)oxazol-5-yl from phenylalanine. 
The premise of this reaction was that introduction ofa catalytic guanidine base, 19, in the 
presence of an azalactone, such as 36 would results in formation of an enolized species; 
followed by successive dissociation ofthe O-acyl group and acylation ofthe a-carbon. 
Initially, reaction conditions discovered by Sterglich in 1970 were investigated. 46 Using a 
catalytic amount of 4-( dimethylamino )pyridine (DMAP) to perform the O-acylated 
azalactone rearrangement, termed the Sterglich rearrangement, illustrated in Scheme 
11-10, was successful in affording of(S)-benzyI4-benzyl-2-(4-methoxyphenyl)-5-oxo-
4,5-dihydrooxazole-4-carboxylate; confrrmed by NMR spectroscopy. 
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vY~ 
Q 
36 0-
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Scheme 11-10: O-acylated azalactone rearrangement, Sterglich rearrangement. 
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Upon successful repetition ofSterglich's work, achiral guanidine 19 was used in place of 
DMAP for catalytic induction. Conversion to product was not observed, however it was 
observed that catalyst 19 was no longer present and a new product had formed, indicated 
by thin layer chromatographic analysis. This unexpected reaction was proposed to be a 
direct result of the guanidine's protons; resulting in an acylated deactivation of the 
catalyst 19, shown in Scheme Scheme II-II. It is hypothesized that alkyl protection of 
these positions, forming a guanidine species such as 8 or 9, would afford the desired 
rearrangement product. However, this work was not further investigated due to a lack of 
N-alkylated guanidines. 
F~FF NH~-F FN --_II 
NH 
F1:MF. F 
If ~ F F 
NH - F 
;)--N 
N )=0 
d 
Scheme 11-11: Proposed method of guanidine inactivation during O-acyl rearrangement. 
4S 
11-2.2. y-Substituted Butenolides 
Continuing to further explore the potential of catalyst 19, focused shifted to the 
development of asymmetric routes for the synthesis ofy-substituented butenolides, a 
structural motif present in numerous natural product, discussed in Section 1-1.1. 
To give entry into this field, y-substitution of3,4-dichloro-2-(5H)-furanone with 
benzaldehyde was investigated, Scheme 11-12. 3,4-dichloro-2-(5H)-furanone was readily 
prepared from a reduction of mucochloric acid.3 It was found that using 5 mol percent of 
catalyst 19 in THF was successful in partial product conversion, Table II-I. No 
diastereotopic or enantiomeric excess were attained with the achiral test guanidine. 
o 0 
Xr50+H~ 
X V 
38:X=CI 
39: X=Br 
X 
catalyst 
THF 
X 
o 
40:X=CI 
41: X=Br 
Scheme 11-12: 'Y-substitution of3,4-dichloro-2-(5.H)-furanone with benzaldehyde. 
After confirming successful induction of y-substitution using the achiral guanidine 
derivative, 19, investigation was directed towards utilizing a chiral catalyst for 
enantioselective induction. For this purpose, the previously discussed guandine with an 
implemented chiral (R)-phenylalaninol auxiliary, 29, was utilized. Investigation for 
asymmetric induction of aforementioned Scheme 11-12 using 38, demonstrated a lower 
reaction time with a 52 percent enantiomeric excess( ee) and mild diastereotopic ratio (dr), 
shown in Table II-I, warranting further investigation. 
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Effort was put forth towards determining the optimal conditions of the catalyst, illustrated 
in Table II-I and Table 11-2. The reaction was found to give the best yields and 
enantioselectivies in THF. Additionally, product conversion was determined to increase 
with time and decrease with low temperatures, however enantioselectivity or 
diastereoselectivity remained largely unchanged. 
T bl II 1 r a e - : Imean dT tV· empera nre arlance 
Entry Time Catalyst Temperature Solvent Percent d.r e.e 
(hr) (5 mol %) caC) Yield (anti:syn) 
Anti Syn 
1 24 19 rt THF 14.0 52.0:48.0 0 0 
2 24 29 rt THF 54.2 61.6:38.4 30 52 
3 5 29 60 THF 20.4 59.2:40.8 31 45 
4 5 29 rt THF 20.0 61.4:38.6 35 49 
5 5 29 0 THF 5.1 58.2:41.8 30 41 
6 5 29 -20 THF <5 59.5:40.5 27 38 
7 5 29 -40 THF <5 57.0:43.0 N.D N.D 
*HPLC results were performed ill duplIcates 
Table 11-2: Various Solvents 
Entry Time Catalyst Solvent Percent d.r e.e 
(hr) (5 mol %) Yield 
(anti:syn) Anti Syn 
1 5 29 THF 20.0 61.4:38.6 35 49 
2 5 29 THF / Acetone 18.0 60.8:39.2 35 46 
3 5 29 Ether 15.2 54.2:45.8 27 37 
4 5 29 TBME 10.1 54.5:45.5 29 37 
*HPLC results were performed ill duplIcates 
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Further investigation ofthis catalyst involved scanning specificity towards a variety of 
derivatives, outlined in Table 11-3. Recent reports show incorporation of bulkier halogens 
on butenolides increase diastereomeric induction.51 In accordance, catalyst 29 was more 
selective with dibromo furanone, 39, in Scheme 11-12, opposed to the dichloro species, 
38. These increases are attributed to by greater steric effects created by the larger bromine 
halogens with the catalyst. Increased interaction results in better asymmetric induction. 
On the other hand, variation of the aldehyde shows minor differences in 
enantioselectivity. These results give insight into the alignment ofthe catalyst during the 
reaction. Since changes in the furanone backbone result in large ee differences, it 
suggests they are most likely positioned near the chiral phenylalaninol auxiliary. 
Mechanistic computational studies are currently ongoing to investigate this reaction. 
Moreover, since aldehydes possess very little influence on ee, they are most likely 
aligned above the biphenyl backbone of catalyst 29, which does not induce 
enantioselectivity, due to its achiral nature. 
Looking further at Table 11-3, it is evident that entries 2 and 4 deviate from the normal 
trends. These entries involve a reaction with dihalofuran-2(5H)-one, 38 and 39 
respectively, with 4-chlorobenzaldehyde. Use of the dichloro species exhibits a 
drastically low ee according to predicted values, while utilizing dibromo furanone affords 
an exceptionally high ee of 96 percent. Computational studies are being performed in this 
area to help rationalize the results. 
Attempts to increase the enantioselective induction ofthe (R)-phenylalaninol catalyst, 29, 
focused towards incorporation of additional chirality. Resulting from the lack of 
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asymmetric induction by the biphenyl backbone, one such attempt focused on 
incorporation of axial chirality using [1,1' -binaphthalene] -2,2'-diamine as a backbone for 
guanidine structure. However, since both (R) and (8) configuration exist, the synergistic 
effects between induction of both chiral functionalities were investigated for constructive 
or destructive selectivity. Preparation of catalysts 31 and 33 was previous discussed in 
section 11-1.3. 
Table 11-3: Guanidine 29 a alyze eaction wit C t I dR . hV aryin2 S b t t u sraes 
Entry Furanone Aldehyde, R % Yield d.r e.e 
(24 hr) 
(X) (anti:syn) Anti Syn 
1 CI C614 54.2 61.6:38.4 30 52 
2 CI 4-CIC6H4 53.0 48.2:51.8 16 20 
3 Br C614 35.0 52.3:47.7 37 61 
4 Br 4-CIC614 30.5 57.8:42.2 54 96 
5 Br 3,5-(OMe )2C614 15.8 54.6:45.4 35 65 
6 Br 4-BrC614 39.5 52.6:47.4 51 51 
7 Br 4-MeC614 19.1 51.0:49.0 37 58 
8 Br Methyl 4- 37.1 53.1:46.9 17 55 
fonnylbenzoate 
9 Br 4-0MeC614 14.6 51.0:49.0 39 55 
10 Br 4-CF3C614 40.5 46.0:54.0 22 53 
*HPLC results were performed m duplIcates 
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Following synthesis, asymmetric induction of the general reaction outlined in Scheme 
II-12, was investigated. These results along with a summary ofthe effects of each 
guanidine species is given in Table II-4. In the cause of utilizing the dichloro furanone, 
38, it is evident that incorporation of (S)-binaphthyl diamine, yielding catalyst 31, 
exhibits mismatched enantiomeric induction with the (D)-phenylalaninol auxilIary. 
However, (R)-binaphthyl diamine exhibits a matched enantiomeric induction, giving a 10 
percent increase in enantioseelctivity. However, unlike the previous catalyst, 29, the 
utilization of a dibromo furanone, 39, offered no increases in enantioselectivity, although 
increases in diastereoselectivity exhibited a 10 percent increase. Future goals are aimed at 
increasing the enantioselectivity and diastereoselectivity ofthese y-substituted butenolide 
reactions, discussed in more depth below. 
T bl II 4 V . a e 
-
: anous C tit a alys S 
Furanone Catalyst (5 mol %) Percent d.r( anti:syn) e.e 
(X) Yield Anti Syn 
CI 19 20.0 52.0:48.0 0 0 
CI 29 54.2 61.4:38.6 35 49 
Br 29 35.0 52.3:47.7 37 61 
CI 31 33.1 59.5:40.5 12 16 
CI 33 31.1 60.1:39.9 42 62 
Br 33 26.1 50.3:49.7 44 64 
*HPLC results were performed ill duplIcates 
so 
11-3. Future Work 
11-3.1. Development of N-alkylated Guanidines 
Future work in this field is focused on preparation of N-methylated guanidine 8 and N-
benzylated guanidine 13, allowing for reassessment of O-acyl azalactone rearrangements 
along with providing catalysts offering new potential asymmetrically inductive properties 
to enantioselective y-substituted butenolides. To date, methylation utilizing butyl lithium 
as a deprotonating agent followed by successive treatment with methyl iodide have been 
unsuccessful. Another potential method for N-methylation involves previously employed 
methods utilizing sodium hydride and methyl iodide, which are not as harsh. 17 N-
benzylation ofthe guanidines can be attempted through methods discussed earlier by 
Kostyanovsk~O, involving alkyl halides, KOH and DMSO. 
P)L 
~ 0-51, 
NH )--/ I -FN 
NH 
Scheme 11-13: Potential Scheme for N-benzylation of phenyl ala nino I guanidines. 
11-3.2. Modification of Axial Chiral Backbone 
Furthermore, work will be directed towards implementation of additional steering groups 
on the binaphthyl backbone, illustrated in Figure 11-2 as RI. Expanding the steric 
bulkiness of the binaphthyl backbone has the potential to generate additional 
asymmetrically inductive effects on the reaction, by increasing the effects of the axial 
chirality. 
51 
R, » 
" OH 
NH ~ )=N 
NH 
Figure 11-2: Guanidine catalyst with potential location for additional Rl attachment groups. 
III. Experimental 
III-I. General Methods 
All reactions were performed under N2 in oven dried glassware. Flash chromatography 
was performed using distilled solvents from Sigma-Aldrich and Caledon. 
Chromatographic purifications were performed using Silicyc1e Siliaflash P60 40-63 /lm 
(230-400 mesh) silica gel with the indicated solvents as eluents. TLC analysis was 
performed using EMD TLC Silica gel 60 F 254 aluminium sheets and visualized using UV 
light, iodine and potassium permanganate and ninhydrin stains. NMR analysis was 
performed using the Bruker 300 Ultrasheild 300 MHz NMR and the Bruker 600 Plus 
Ultrasheild 600 MHz NMR. Optical rotations were determined using the Autopol III 
automatic polarimeter. Mass spectroscopy analysis was performed using the Kratos 
Analytical! MSI Concept 1 S. 
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ill-2. General Procedures 
ill-2.1. Approaches to Guanidines Utilizing lminium Chloride and Amine Coupling 
General procedure for synthesis of SH-dibenzo[d,t] [1,3]diazepin-6(7H)-one (3): 
AcOH NH 
';=0 
NH reflux,3h 
Following the reported procedure30, AcOH was added to a mixture of2,2'-
diaminobiphenyl (1 equiv.) and urea (2 equiv.) and the solution was refluxed for 3 hours. 
The solution was diluted with isoproponal and cooled in an ice bath. The residue was 
filtered, washed with isoproponal and dried in vacuo, yielding biphenyl urea (70% yield). 
Recrystallization was performed from BuOH, resulting in an off-white powder. 1H NMR 
(DMSO, 300 MHz) 08.793 (s, 2H, N-H), 7.469-7.443 (m, 2H, Ar-H), 7.305-7.302 (m, 
2H, Ar-H), 7.184-7.082 (m, 4H, Ar-H). 
General procedure for synthesis of S,7-dimethyl-SH-dibenzo[d,t][1,3]diazepin-
6(7H)-one (4): 
NH 
';=0 
NH 
NaH, Mel 
DMF 
/ 
N 
';=0 
N 
\ 
Following the procedure by Isobe et al,17 NaH (55% in mineral oil, 2.2 equiv.) washed 
with dry hexanes under N2, followed by suspension in DMF. Biphenyl urea (1 equiv.), 
was dissolve dissolved in DMF and added dropwise to the stirred suspension ofNaH and 
was let stir at room temperature for 1 hour. Iodomethane (2.2 equiv.) was then added 
S3 
dropwise to the mixture and let stir at room temperature overnight. The reaction was 
poured into 5% HCI and extracted with dichloromethane (2 x 100mI). The organic layer 
was washed with water and dried with MgS04. Purification ofthe residue by column 
chromatography and recrystallization in MeOH afforded the product as colourless prisms 
(95% yield). IH NMR (CDCb, 300 MHz) 87.519 -7.211 (m, 8H, Ar-H), 3.228 (s, 6H, 
CH3). BC NMR (CDCb, 300 MHz) 8 166.02, 144.93, 132.90, 128.67, 128.46, 124.83, 
119.75,36.33. 
General procedure for synthesis of 6-chloro-5,7-dimethyl-5H-
dibenzo[d,t] [1,3]diazepin-7-ium chloride (5): 
GCI 
/ $/ 
N (COClh N 
FO • }-CI reflux N N 
"'- \ 
5,7-dimethyl-5H-dibenzo[d,f][1,3]diazepin-6(7H)-one (1 equiv.) was added to a reflux 
apparatus and put under and N2 atmosphere. Oxalyl chloride (5 equiv.) was added, 
followed by a catalytic amount ofDMF (2 drops). The reaction was heated to 60°C and 
let stir overnight. Excess oxalyl chloride was removed under reduce pressure, yielding the 
product (60% conversion) as a yellow solid. No further purification was performed. 
Product conversion was determined by NMR. IH NMR (CDCb, 300 MHz) 83.922 
(Chloroiminium: N- CH3), 3.192 (Urea: N- CH3). 
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General procedure for synthesis of N-(S,7-dimethyl-SH-dibenzo[d,f] [l,3]diazepin-
6(7H)-ylidene )-l-phenylmethanamine (7): 
NEta, CH2CI2, 
rt,24hr 
~J <) 
N 
\ 
According to the reported procedure43, to a solution of benzyl amine (1 equiv.) in DCM 
(0. 18M) was added NEt3 (2 equiv.). This mixture was added dropwise to a stirred 
solution of6-chloro-5,7-dimethyl-5H-dibenzo[d,f] [1,3]diazepin-7-ium. The mixture was 
stirred at room temperature for 6 hours, poured into 5% HCl, and extracted with DCM. 
The solvent was evaporated and the residue was dissolved in water, and washed with 
toluene (2 x 50ml). The aqueous solution was made basic with 5% NaOH, extracted with 
water and dried over Na2S04. Solvent evaporation yielded the pure guanidine (76% yield) 
as a white solid. Column chromatography could also be used for purification. White 
crystals. IH NMR (CDCh, 300 MHz) 0 7.587 - 7.203 (m, 13H, Ar-H), 4.829 (s, 2H, N-
H), 3.356 (s, 3H, N- CH3), 3.166 (s, 3H, N- CH3). 13C NMR (CDCh, 300 MHz) 0 160.22, 
145.66, 145.51, 143.00, 137.91, 136.62, 133.89, 129.12, 128.71, 128.53, 128.47, 128.40, 
128.31, 126.45, 126.25, 125.89, 125.39, 124.54, 121.85,52.74,40.71,38.50. mlz = 327. 
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General procedure for synthesis of 5, 7-dibenzyl-5H-dibenzo[ d,f] [1,3]diazepin-6(7H)-
one (10): 
• 
9 
N 
FO 
NH 
FO KOH, DMSO NH 6 
Biphenyl urea (1 equiv) and crushed KOH (4 equiv) were dissolved in DMSO (1.25 M), 
followed by the addition of benzyl bromide (4 equiv.) and was let stir overnight. Water 
was added, forming an amorphous precipitate which was filtered off and dried under 
vacuum. To remove any residual DMSO, the compound was recrystallized using EtOH 
(Yield 65%). Off-white crystals. lH NMR (CDCh, 300 MHz) & 7.504-7.499 (m, 2H, Ar-
H), 7.479-7.214 (m, 7H, Ar-H), 7.105-7.093 (m, 6H, Ar-H), 6.961-6.931 (m, 4H, Ar-H): 
5.213-5.162 (d, 2H, CH2), 4.702-4.652 (d, 2H, CH2). 13C NMR (CDCh, 300 MHz) & 
164.93, 143.43, 137.64, 134.09, 128.41, 128.19, 127.24, 126.79, 125.27, 121.23,52.03. 
General procedure for synthesis of 5,7-dibenzyl-5H-dibenzo[d,f] [1,3]diazepine-
6(7H)-thione (11): 
(Lawesson's Reagent) 
• 
o-xylene, 145°C,24hr 
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Benzyl urea (1 equiv.) and Lawesson's reagent (2 equiv.) were dissolved in a-xylene 
(0.24M in respect to benzyl urea). The mixture was heated to 145°C and let stir for 24 
hours. The reaction was quenched using a 3.75:1 biphasic solution of methanol and 5% 
aqueous HCI and was let stir at room temperature overnight. The organic layer was 
isolated and the aqueous phase was extracted with toluene. The organic layers were 
combined, washed with water and brine, dried over MgS04 and evaporated. The residue 
was purified by column chromatography (Si02, hexane:ethyl acetate, 50: 1) affording the 
product. Recrystallization from ether-hexanes gave white crystals (91 % yield). IH NMR 
(CDCh, 300 MHz) b 7.415-7.270 (m, 8H, Ar-H), 7.061-7.7.038 (m, 6H, Ar-H), 6.861-
6.830 (m, 4H, Ar-H), 5.840-5.789 (d, 2H, CH2), 4.896-4.845 (d, 2H, CH2). BC NMR 
(CDCh, 300 MHz) b 199.48, 145.58, 136.93, 135.53, 128.41, 128.01, 127.86, 127.58, 
126.81, 126.45, 122.06,57.42. 
111-2.2. Approaches to Guanidines Utilizing DMC-Induced Thiourea Cyzllzation 
General procedure for synthesis of 2-chloro-l,3-dimethyl-lH-imidazol-3-ium 
chloride: 
(COCI)2 
DCM, 1 drop DMF 
reflux, 5 hr 
1,3-dimethyl-2-imidazolidinone (1 equiv.) under an N2 atmosphere was dissolved in dry 
DCM. Oxalyl chloride (1.5 equiv.) was added, followed by a catalytic amount ofDMF 
and the reaction was set to reflux for 5 hours. The solvent was removed under reduced 
pressure and the resulting solid was washed with ether (3 washes) under an N2 
atmosphere, yielding 85% product as yellow crystals. 
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m-2.2.1. Biphenyldiamine Backbone with a Trifluoro Auxiliary 
General procedure for the generation of N-(2'-amino-[I,1 '-biphenyl]-2-yl)acetamide 
(14): 
A~O/AcOH 
oeM 
Following a slight modification ofthe reported procedure, l [1,1 '-biphenyl]-2,2'-diamine 
(1 equiv) was dissolved in dry CH2Ch (0. 1M), followed by addition of AcOH (10 eq.) 
under N2. After 10 minutes, acetic anhydride (0.9 equiv) was added drop wise at 0 DC 
under N2. The solution was let stirred overnight at room temperature and then neutralized 
to a pH::::7 by addition of2NNaOH. The reaction mixture was extracted with CH2Ch (3 x 
25 mL), the organic layers were combined, washed with saturated brine (25 mL) and 
dried over MgS04. The mixture was concentrated in vacuo and the residue was purified , 
by column chromatography to give 78% yield. Beige crystals. IH NMR (CDCh, 300 
MHz) 8 8.226-8.199 (d, IH, Ar-H), 7.507 (s, IH, N-H), 7.425-6.806 (m, 7H, Ar-H), 
3.623 (s, 2H, NH2), 2.011 (s, 3H, CH3). BC NMR (CDCh, 300 MHz) 8 168.56, 143.56, 
135.68, 131.16, 130.74, 129.44, 129.28, 128.71, 124.70, 123.52, 122.25, 119.29, 115.70, 
24.67. 
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General procedure for synthesis of the corresponding biphenyl diamine thiourea, N-
(2'-(3-(3,5-his(trifluoromethyl)phenyl)thioureido)-[I,1 '-biphenyl]-2-yl)acetamide 
(16): 
NH 
r 
S=C=N 
F 
F F 
OCM,ODC 
F. F F~ . FF 
S >J-t-F 
}--NH 
NH 
NH 
r 
Following a reported procedure,55 the previously prepared N-(2'-amino-[I, I '-biphenyl]-2-
yl)acetamide (1 equiv) was dissolved in dry CH2Ch (0.06M) and 3,5-
bis(trifluoromethyl)phenyl isothiocyanate (1.2 equiv) was added dropwise at O°C under 
N2. The solution was stirred overnight at room temperature. The mixture was 
concentrated in vacuo and purified by flash chromatography (Ethyl Acetate:Hexanes 
• 
1:10) to give 95% yield. Yellow tinged solid. IH NMR (CDCh, 300 MHz) b 7.802-7.319 
(11H, Ar-H) 1.884 (s, 3H, CH3). BC NMR (CDCh, 300 MHz) b 179.99, 168.68, 141.96, 
136.44, 135.85, 135.43, 131.08, 130.39, 130.26, 129.83, 129.04, 128.78, 128.42, 127.36, 
125.44, 125.13, 124.39, 121.83, 117.37,23.64. 
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General procedure for the synthesis of 1-(6-«3,S-his(trifluoromethyl)phenyl)imino)-
6, 7-dihydro-SH-dibenzo[d,t] [1,3]diazepin-S-yl)ethanone (18): 
F~ FF 
S ~-F 
}-NH 
NH MeCN, Et3N 
900C 
NH 
>=N 
N 
r 
F. F 
F 
F 
F F 
Cyclization to the subsequent guanidinium species was achieved by dissolving the 
prepared N-(2'-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido )-[1,1 '-biphenyl]-2-
yl)acetamide (1 equiv) and DMC (2-chloro-l,3-dimethylimidazolinium chloride) (1.2 
equiv.) in MeCN (0.0151M), adding Et3N (3 equiv.) and refluxing the mixture. Work up 
involved addition of the reaction mixture to water and extraction by CH2Ch (2x 30 mL). 
Purification by column chromatography (Si02) (Ethyl Acetate:Hexane 1 :2) to give 79%-
yield ofguanidinium species. Yellow oil. IH NMR (CDCh, 300 MHz) b 9.318 (s, IH, N-
H), 8.182-7.240 (l1H, Ar-H), 1.893 (s, 3H, CH3). l3C NMR (CDCh, 300 MHz) b 144.22, 
141.54, 140.93, 138.65, 136.33, 131.69, 131.24, 129.95, 129.77, 129.52, 129.37, 129.03, 
128.82, 127.42, 126.76, 125.01, 124.23, 121.40, 117.86, 115.69,22.65. 
General procedure for the synthesis of N-(SH-dibenzo[d,f] [1,3]diazepin-6(7H)-
ylidene)-3,S-bis(trifluoromethyl)aniline (19): 
F~ F 
NH ~F 10% MeONa )=N -----MeOH 
N 
FbiF. F 
f ~ F F 
NH - F )=N 
NH 
r 
The acyl protecting group of previously prepared 1-(6-«3,5-
bis(trifluoromethyl)phenyl)imino)-6,7-dihydro-5H-dibenzo[d,f][1 ,3]diazepin-5-
yl)ethanone (1 equiv.) was removed by treatment with 10% MeONa in MeOH for 
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1.5hours at room temperature. The resulting solution was poured into water and extracted 
with CH2Ch (2x 30 mL). The obtained residue was purified by column chromatography 
(Si02) to give 90% yield of product. White powder after crystallization. 1 H NMR 
(CDCh, 300 MHz) D 7.540-7.004 (8H, Ar-H), 6.656, (s, IH, N-H), 5.756 (s, IH, N-H). 
13C NMR (CDCh, 300 MHz) D 158.985, 149.467, 133.645, 133.206, 132.769, 132.330, 
129.500, 129.008, 125.417, 125.074, 123.680, 121.454, 116.421. rn/z = 327. 
ill-2.2.2. Binaphthyldiamine Backbone with a Trifluoro Auxiliary 
The general procedures outlined above were also followed for the synthesis of guandines 
containing binaphthyl backbones. 
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(S)-N-(2'-amino-l,1 '-hinaphthyl-2-yl) acetamide 
N)( 
o 
Clear colorless oil. IH NMR (CDCh, 300MHz) () 8.650 (d, IH; RNHOCH3), 8.001 (d, 
IH; Ar-H), 7.872 (multiplet, 3H; Ar-H), 7.415 (t, lH; Ar-H), 7.181 (multiplet, 5H; Ar-
H), 6.919 (d, IH, Ar-H), 3.682 (s, 2H; NH2), 1.873 (s, IH; OCH3). 13C NMR (CDCh, 300 
MHz) () 168.73, 142.78, 135.11, 133.63, 132.41, 131.31, 130.38, 129.24, 128.25, 128.24, 
127.33, 126.84, 125.46, 125.14, 123.65, 122.75, 120.94, 120.54, 118.09, 110.37,24.73. 
m/z= 326. 
(S)-N-(2'-(3-(3,5-his(trifluoromethyl)phenyl)thioureido)-1,1 '-hinaphthyl-2-
yl)acetamide 
F. F Fh .FF 
s ~-F 
}-NH 
NH 
NH 
r 
Yellow tinged solid. 1 HNMR (CDCh, 300 MHz) () 7.984 (multiplet, 8H; Ar-H), 7.625 
(s, IH; Ar-H), 7.475 (multiplet, 2H; Ar-H), 7.246 (multiplet, 3H; Ar-H), 7.036 (d, 2H; 
Ar-H) 1.747 (s, lH; OCH3) 13CNMR (CDCh, 300 MHz) () 181.15, 170.89, 141.02, 
135.68, 134.35, 132.94, 132.74, 132.49, 131.98, 131.85, 131.40, 130.97, 130.53, 128.85, 
128.13, 126.91, 126.54, 126.42, 126.36, 125.92, 125.54, 125.51, 125.26, 125.00, 123.96, 
123.13,121.40, 117.16, 117.12, 78.05,21.74.m/z=597. 
(S)-I-( 4-(3,S-his( trifluoromethyl)phenylimino )-4,S-dihydro-3H -dinaphtho [2,1-
d: 1 ',2 '-t] [1,3]diazepin-3-yl)ethanone 
F. F 
F 
NH )=N 
N 
r 
Yellow solid. IH NMR (CDCh, 300 MHz) 8 9.723 (s, lH; NH), 8.241 (s, 1H; Ar-H), 
8.031 (multiplet, 3H; Ar-H), 7.935 (d, 1H;Ar-H), 7.787 (d, 1H; Ar-H), 7.627 (d, 1H;Ar-
H) , 7.494 (multiplet, 4H; Ar-H), 7.335 (multiplet, 3H; Ar-H) 2.060 (s, lH, OCH3). 13C 
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NMR (CDCh, 300 MHz) 8 170.27, 145.06, 143.78, 140.64, 138.95, 133.54, 132.43, 
131.83, 131.61, 131.39, 131.24, 131.17, 130.61, 130.52, 129.95, 128.68, 128.46, 128.40, 
127.11, 126.99, 126.95, 126.13, 125.99, 125.91, 124.85, 124.10, 123.63, 122.36, 122.29 
120.49, 117.92, 115.86,21.95. m/z = 563. 
(S)-N-(3H-dinaphtho[2,I-d: 1 ',2 '-t] [1,3]diazepin-4(SH)-ylidene)-3,S-his 
(trifluoromethyl)aniline (21) 
F. F 
F 
~ 
Off-white solid. IH NMR (CDCh, 300 MHz) 8 7.933 (d, 2H; Ar-H), 7.902 (d, 2H; Ar-H), 
7.609 (s, 1H; Ar-H), 7.426 (s, 4H; Ar-H), 7.358 (d, 1H; Ar-H), 7.206 (multiplet, 4H; Ar-
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H), 6.982 (s, 2H; Ar-H), 5.948 (s, 1H, Ar-H). 13C NMR (CDCh, 300 MHz) b 160.17, 
149.41, 140.22, 138.49, 133.38, 133.16, 132.94, 132.72, 132.38, 131.43, 131.32, 130.09, 
129.92, 128.20, 127.31, 127.13, 126.54, 126.42, 125.98, 125.38, 125.12, 124.89, 124.17, 
123.74, 123.55, 122.36, 121.63, 120.56, 120.23, 116.60. mlz = 521. 
m-2.2.3. Biphenyldiamine Backbone with a Phenylalaninol Auxiliary 
General procedure for synthesis of (R)-2-amino-3-phenylpropan-l-ol (23): 
P 1. NaBH4fTHF p 2. 12fTHF, O°C .. 
H2N~OH 3. Reflux,1Shr ". OH }-I 4. 20% KOH, 5hr 
0 H2N 
Following a procedure reported by Brenna et al.,59 phenylalanine (1equiv.) was slowly 
added to a stirred suspension ofNaBH4 in THF (2.5 equiv.) and subsequently cooled to 
O°C. A solution ofh (1 equiv.) in THF was prepared and added drop wise, maintaining a 
temperature below 20°C. Once evolution ofH2 had ceased after addition ofb was 
complete, the reaction was refluxed overnight. After cooling the reaction to room 
temperature, MeOH was added to exhaust excess NaBH4 and let stir for 45 minutes. The 
solvent was evaporated under N2 and the residual white paste was dissolved in 20% 
(w/w) KOH and stirred for 4 hours. The mixture was extracted with dichloromethane (3 x 
50mL), dried with NaS04 and solvent was removed by rotary evaporation, yielding a 
white solid. (80% yield). 
General procedure for synthesis of (R)-1-«tert-butyldimethylsilyl)oxy)-3-
phenylpropan-2-amine (24): 
TBDMSCI 
DCM. rt 
.. 
Following a procedure by Ishikawa et aI.,18 TBDMSCI (1 equiv) was dissolved in dry 
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dichloromethane under an N2 atmosphere. The solution was added dropwise to a solution 
of (S)-phenylalaninol (1equiv.), 4-(dimethylamino) pyridine (0.2 equiv.), Et3N (2 equiv.) 
in dichloromethane (0.66M with respect to phenylalaninol). The reaction was stirred at 
room temperature for 24 hours and poured into water; followed by extraction with DCM. 
The obtained residue was purified through column chromatography (Si02, 10:1 
hexanes:ethyl acetate) yeilding 90% product. 
General procedure for synthesis of (R)-tert-butyl(2-isothiocyanato-3-
phenylpropoxy) dimethylsilane (26): 
The TBDMS protected phenylalaninol (1 equiv.) was dissolved in DCM (giving 0.167M 
solution) under an N2 atmosphere, followed by addition ofEt3N. After 5 minutes CS2 was 
added dropwise and the reaction was let stir for 2 hours at room temperature. This was 
followed by addition of a 1.2 M solution ofDMC (1.2 equiv.) in DCM. The reaction was 
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let stir at room temperature for 24 hours and evaporated Purification by column 
chromatography gave the product (96% yield) as a colourless oil. 
General procedure for synthesis of (R)-1-(2'-amino-[1,1 '-biphenyl]-2-yl)-3-(1-«tert-
butyldimethylsilyl)oxy)-3-phenylpropan-2-yl)thiourea (27): 
P)L OCM NH2 reflux 
+ 
NH2 ~/-_p-~I, 
S=C=N 
• 
P~ ~ ~ ~ 
S -: O-Si J.-)--../ I" N N 
H H 
2,2'-diaminobiphenyl (1 equiv.) and the TDBMS protected phenylalaninol thioisocyanate 
(1 equiv.) were dissolved in DCM and refluxed for 24 hours. Following evaporation, the 
residue was purified through column chromatography (Si02, 5:1 hexanes:ethyl acetate). 
The product was obtained in 95% yield after recovery of starting materials, which were • 
resubjected to the reaction conditions. Clear and colourless oil. IH NMR (DMSO, 300 
MHz) 0 8.877-8.812 (d, IH; N-H), 7.432-6.606 (m, 13H; Ar-H), 4.716-4.647 (d, 2H, 
NH2), 4.559 (m, IH, CH), 3.507-3.456 (m, 2H, CH2), 2.868-2.770 (m, 2H, CH2), 0.861 
(s, 9H, 3CH3), 0.020 (s, 6H, 2CH3). 13C NMR (CDCh, 300 MHz) Rotamers Present. 0 
179.70,179.44, 142.99, 149.89, 138.12, 135.34, 135.03, 132.51, 130.57,129.50,129.45, 
129.07, 128.48, 128.41, 127.52, 127.31, 126.48, 126.37, 125.99, 125.10, 124.82, 119.75, 
116.80, 116.67,61.56,57.34,57.16,36.40,36.27,25.86,25.80, 18.13, 18.06, -5.53,,, 
5.69. 
General procedure for synthesis of (R)-I-«tert-butyldimethylsilyl)oxy)-N-(SH-
dibenzo [d,f] [1,3] diazepin-6(7H)-ylidene )-3-phenylpropan-2-amine (28): 
P?L 
.-, O-SI, 
S )-I I 
}--NH 
NH MeCN 
reflux 
.. 
Thiourea (1 equiv.) and DMC (1.2 equiv.) were dissolved in MeCN under an N2 
atmosphere. Et3N (3 equiv.) was added and the mixture was set to reflux for 13 hours. 
The reaction was then poured into water and extracted with DCM. The residue was 
purified by column chromatography (Si02, 5:1 Hexanes:Ethyl acetate) affording the 
product (85% yield) as a colourless oil. IH NMR (CDCh, 300 MHz) 6 7.433-7.132 (m, 
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13H; Ar-H), 4.015 (m, IH; CH), 3.761-3.703 (m, IH; CH2), 3.618-3.569 (m, IH, CH2), 
2.961-2.941 (dd, IH, CH2), 2.864-2.858 (dd, IH, CH2), 0.887 (s, 9H, 3CH3), 0.044-0.036 
(d, 6H, 2CH3). 
General procedure for synthesis of (R)-2-«SH-dibenzo[d,f] [1,3]diazepin-6(7H)-
ylidene ) amino )-3-phenylpropan-l-01 (29): 
TBAF, THF 
rt 
... 
P 
.-, OH 
NH )-I FN 
I NH 
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The cyc1ized guanidine was dissolved in THF under N2(g), followed the the addition of 
1M TBAF in THF. The mixture was let stir for 2 hours at room temperature and then 
poured into aqueous 5% NaOH solution and extracted with DCM. The residue was 
purified through coloumn chromatography (Si02, 1: 1 Hexanes:Ethyl acetate) to afford the 
product (92% yield) a colourless oil. Washing with hexanes crashed the product out as a 
white precipitate. IH NMR (CDCh, 300 MHz) 8 7.3776.937 (m, 13H; Ar-H), 3.958-
3.889 (m, IH; CH), 3.675-3.633 (dd, IH; CH2), 3.515-3.480 (m, IH, CH2), 2.863-2.792 
(dd, IH, CH2), 2.680-2.611 (dd, IH, CH2), 0.887 (s, 9H, 3CH3), 0.044-0.036 (d, 6H, 
2CH3). BC NMR (CDCh, 300 MHz) 8160.57, 141.98, 137.20, 131.29, 129.63, 129.47, 
129.18, 128.99, 128.79, 128.76, 128.52, 126.87, 125.55,66.74,58.01,37.31. mlz = 343. 
ID-2.2.4. Binaphthyldiamine Backbone with a Phenylalaninol Auxiliary 
The general procedures outlined above, were also employed for the synthesis ofthe (R)-
(+) and (8)-(-) binaphthyl compounds outlined in place of the biphenyl backbone. 
(S)-( -)-binaphthyl phenylalaninol guanidine catalyst 31. 
White powder after crystallization. 1H NMR (CDCh, 300 MHz) 8 7.9127.845 (m, 5H; Ar-
H), 7.422-7.063 (m, 12 Ar-H), 3.804-3.774 (m, IH; CH2), 3.734-3.704 (m, IH; CH), 
13 . 3.011-2.932 (m, 2H, CH2). C NMR (CDCh, 300 MHz) 8 160.58, 141.98, 137.20, 
68 
131.30, 129.63, 129.56, 129.47, 129.18, 128.99, 128.79, 128.76, 128.87, 125.55, 125.19, 
66.74,58.01,37.31. mlz = 443 
(R)-(-)-binaphthyl phenylalaninol guanidine catalyst 33. 
p 
~ OH 
NH )--I FN 
NH 
White powder after crystallization. IH NMR (CDCh, 300 MHz) 87.9127.845 (Ill, 5H; 
Ar-H), 7.422-7.063 (Ill, 12 Ar-H), 3.804-3.774 (Ill, 1H; CH2), 3.734-3.704 (Ill, 1H; CH), 
3.011-2.932 (Ill, 2H, CH2). 13C NMR (CDCh, 300 MHz) 8 163.10, 142.95, 137.10, 
132.28, 131.44, 129.30, 129.16, 128.98, 128.61, 128.00, 127.01, 126.69, 126.02, 124.96. 
mlz=443 
ill-3. O-acyl Azalactone Rearrangement and Reactant Preparation 
General procedure for synthesis of (R)-2-( 4-methoxybenzamido )-3-phenylpropanoic 
acid (34): 
1. NaOH, H20 
Ether,O°C 
2. 8.5M NaOH 
COlO 
I~ 
A 
0 ..... 
3.HCI 
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Following a protocol employed by Fu et aI.,10 (D)-phenylalanine (1 equiv.) was dissolved 
in a 3.4M solution ofNaOH (1.1 equiv.). Subsequently, ether (5 x water volume) was 
added and the reaction was..cooled to O°C. p-Anisoyl chloride and an 8.5M solution of 
NaOH (1.1 equiv.) were alternately added over 1.5 hours and the reaction was let warm 
to room temperature overnight. Ether was then removed by rotoevaporation and 
concentrated HCI was added to the residue resulting in precipitation ofthe product. 
Recrystallization was achieved with hot acetone yielding the product as white crystals. 
(80% yield). Comparison ofNMR data to literature confrrmed product. 10 
General procedure for synthesis of (R)-4-benzyl-2-( 4-methoxyphenyl)oxazol-5( 4H)-
one (35): 
o-N=C=N-Q 
.. V "" Jl ': .~~ Q 
0-
Following a protocol employed by Fu et aI.,1O a solution of N,N-
dicyclohexylcarbodiimide (DCC) (1 equiv.) in DCM (O.83M) was added dropwise to a 
O°C mixture of N-anisoyl-(D)-phenylalanine (1 equiv.) in DCM (0. 19M). The resulting 
mixture was let stir overnight, allowing for warming to room temperature. The resulting 
precipitate was removed by filtration and the solvent ofthe resulting solution was 
removed by rotoevaporation affording a white solid. Recrystallization was achieved using 
a 4: 1 pentane:DCM in a freezer. Crystals were washed with cold pentane and dried in 
vacuum, affording the product (70% yield). Comparison ofNMR data to literature 
confrrmed product. 10 
General procedure for synthesis of benzyl (4-benzyl-2-( 4-methoxyphenyl)oxazol-5-
yl) carbonate (36): 
V 'II. 1 I: .~~ 
Q 
0-
o ~~ \;:::J 0 0 
Vi~ 
Q 
0 -
Following a protocol employed by Fu et aI.,10 a solution of2-(4-methoxyphenyl)-4-
70 
benzyloxazalone (I equiv.) in THF (0.05M) was cooled to O°C and NEt3 was then added 
(1.1 equiv.). Followed was the addition of benzyl chloroformate (1.05 equiv.), forming a 
white precipitate and the mixture was stirred overnight. THF was evaporated and the 
resulting residue was dissolved with ether and partitioned with 1M HCI (1:1). The 
organic layer was separated, washed with 1M HC~ followed by brine, and dried over 
MgS04. Evaporation of solvent gave a residue which was purified by flash 
chromatography (Si02, ether:pentane, 1:9 followed by 1 :4) affording the product as a 
yellow oil (67% yield). Comparison ofNMR data to literature confrrmed product.10 
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General procedure for synthesis of (S)-benzyI4-benzyl-2-( 4-methoxyphenyl)-5-oxo-
4,5-dihydrooxazole-4-carboxylate (37): 
C\ 
O~O 
= 0 DMAP (10 mol %) 
t-amyl alcohol 
~I 
~ 
0, 
According to literature,lo benzyl (4-benzyl-2-( 4-methoxyphenyl)oxazol-5-yl) carbonate 
(1 equiv.) was dissolved with t-amyl alcohol in an N2 atmosphere, in a vial equipped with 
a stir bar, affording a O.25M solution. Additionally, the catalyst (DMAP or guanidine 
catalyst) (10 mol %) was dissolved in a separate vial with t-amyl alcohol. Both solutions 
were cooled in an ice bath, followed by cannulation of catalyst solution to the azalactone 
solution. Reaction completion was determined by NMR as compounds are sensitive to 
ShOo Comparison ofNMR data to literature confrrmed product. tO 
ill-4. Vinylogous Aldol Reaction 
A general procedure for synthesis of 3,4-dichlorofuran-2(5H)-one (38, 39): 
NaBH4• MeOH. aoc 
H2S04• MeOH. aoc 
Following a protocol employed by Bellina et al.,3 Mucochloric acid (1 equiv.) was 
dissolved MeOH (giving a O.66M solution) and cooled to O°C. Sodium borohydride (1.5 
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equiv.) was added portionwise and then stirred for 30 minutes. A 2M solution of 
concentrated sulfuric acid (1 equiv.) in methanol, cooled to O°C, was then added to the 
reaction. The mixture was kept cold for 10 minutes and then concentrated under reduce 
pressure. The residue was washed with brine (4 x MeOH volume) and extracted with 
diethyl ether (5 x (2 x MeOH volume». The extract was dried under reduced pressure and 
recrystalized from 1: 1 pentane:diethyl ether giving pure product as a colourless solid, in 
88% yield. Spectral properties are in satisfactory agreement with reported values. 3 
ill-4.1. Generation of Vinylogous Aldol Adducts 
General procedure for synthesis of 3,4-dihalo-S-«R)-hydroxy(phenyl)methyl)furan-
2(SH)-one: 
The following protocol was employed for the generation ofthe all vinylogous aldol 
adducts listed in Table 11-3. 
o 
x 
catalyst 
THF 
x 
A solution of3,4-dihalo-2-(5H)-furanone (1 equiv.) and benzaldehyde were prepared in 
THF (0.5mL). To this solution, catalyst (5 mol %) was added and the reaction was let stir 
for 5 hours to 24 hours. The reaction was quenched using saturated aqueous NH4CI, 
extracted with ethyl acetate and dried over Na2S04. The solvent was evaporated, giving a 
residue that was purified by column chromatography (Si02, hexanes:ethyl acetate, 5:1) 
affording the product in various yields dependent on conditions. 
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IV. Appendix 
IV-t. NMR Spectras 
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Figure IV-I: Biphenyl urea IH-NMR (DMSO, 300MHz) 
IV -1.2. Dimethylbiphenyl urea (4) 
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Figure IV-2: Dimethylbiphenyl urea IH-NMR (CDCh, 300MHz). 
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Figure IV-3: Dimethylbiphenyl urea 13C-NMR (CDCh, 300MHz). 
IV-1.3. 6-chloro-5,7-dimethyl-5H-dibenzo[d,t] [1,3]diazepin-7-ium chloride (5): 
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FROCNO "1 
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Figure IV -4: 6-chloro-5, 7-dimethyl-5H-dibenzo[ d,t] [1,3Jdiazepin-7-ium chloride IH-NMR 
(CDCI3). 
IV -1.4. N-(5, 7 -dimethyl-5H-dibenzo [d,t] [1,3] diazepin-6(7H)-ylidene )-1-
phenylmethanamine (7) 
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Figure IV -5: N-(5, 7 -dimethyl-5H-dibenzo[ d,f] [1,3]diazepin-6(7H)-ylidene)-1-
phenylmethanamine IH_NMR (CDCl3). 
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Figure IV -6: N-(5, 7-dimethyl-5H -dibenzo [d,t] [1,3]diazepin-6(7H)-ylidene )-1-
phenylmethanamine 13C-NMR (CDCl3). 
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IV -1.5. 5,7 -dibenzyl-5H-dibenzo [d,f] [1,3]diazepin .. 6(7H)-one (10) 
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NAME Pl.09060S--benzylat.ion 
EXPNO 1 
PROCNO 1 
Date 20090610 
Tlme- 12.22 
H l STRUM spect 
PROBRO 5 rom PABBO BE-
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NS 8 
DS 0 
SWH 6172 _ 1 39 Hz 
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AU 2.6542580 sec 
RG 181 
OW 81. 000 usee 
DE 6.00 usee 
TE 290.6 K 
D1 1 .00000000 sec 
T'OO 1 
.. ,.."" ... "''''' .. '''' CHANNEL f1 ===""='=== 
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PLI 0.00 dB 
PL1W 30. 14263125 W 
SJ.o"Ol 300 . 131 B53~ MUz 
51 16384 
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W~ ~ 
5SB 0 
t.B 0.30 Hz 
GB 0 
'P.C 1. 00 
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Figure 1V-7: 5,7-dibenzyl-5H-dibenzo[d,t] [l,3]diazepin-6(7H)-one IH_NMR (CDCh). 
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Figure IV-S: : 5,7-dibenzyI-5H-dibenzo[d,t] [1,3]diazepin-6(7H)-one 13C-NMR (CDCI3). 
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IV-l.6. 5,7-dibenzyl-5H-dibenzo[d,t] [1,3]diazepine-6(7H)-thione (11) 
\><J BRUKER 
L.X-J 
NAME -PL090720-thl~)t)!'!!nzylurf?a 
~;X'P,NO J 
PROCNO 1 
n~1;:1!' 2{)f)9iY122 
hme 12 .0B 
INS1.'RUM spect 
PRaSHD 5 rom PASBO 8.8-
P.UJ.PltOG ;;0;930 
TO ~76e 
sor.vb"'N'l' CDeB 
NS a 
DS 0 
SNH 6172:.8.39 .liz 
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TE 291.3 K 
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===="""" CUANNEL fl =","'==== 
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Pi 10.20 u,~ec 
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SJ:.' 300.1300000 M.f1z 
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Figure IV -9: 5, 7-dibenzyl-5H-dibenzo[ d,t] [1,3Jdiazepine-6(7H)-thione IH-NMR (CDCI3). 
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Figure IV-lO: 5,7-dibenzyl-5H-dibenzo[d,f][l,3]diazepine-6(7H)-thione 13C-NMR (CDCh). 
IV-I.7. N-(2'-amino-[I,1 '-biphenyl]-2-yl)acetamide (14) 
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Figure IV-ll: N-(2'-amino-[1,1'-bipbenyIJ-2-yl)acetamide IH-NMR (CDCI3). 
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'I'E 298.5 K 
D1 2 . 00000000 sec 
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Figure IV-12: N-(2'-amino-[1,1'-biphenyIJ-2-yl)acetamide 13C_NMR (CDCl3). 
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IV -l.S. N-(2' -(3-(3,S-his(trifluoromethyl)phenyl)thioureido)-[1,1 '-hiphenyl]-2-
yl)acetamide (16) 
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Figure IV -13: N-(2'-(3-(3,S-bis(trifluoromethyl)phenyl)thioureido )-[1,1 '-biphenyl]-2-
yl)acetamide IH-NMR (CDCh). 
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Figure IV -14: N-(2 '-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido )-[1,1 '-biphenyl]-2-
yl)acetamide 13C_NMR (CDCI3). 
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IV-l.9. 1-(6-«3,S-bis(trifluorometbyl)pbenyl)imino)-6,7-dibydro-SH-dibenzo[d,f]-
[1,3]diazepin-S-yl)etbanone (18) 
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Figure IV-IS: 1-(6-«3,S-bis(tritluoromethyl)phenyl)imino )-6, 7-dihydro-SH-dibenzo [d,t] [1,3] 
diazepin-S-yl)ethanone IH-NMR (CDCh). 
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Figure IV -16: 1-( 6-«3,5-bis(trifluoromethyl)phenyl)imino )-6, 7-dihydro-5H-dibenzo [d,t] [1,3J 
diazepin-5-yl)ethanone 13C-NMR (CDCI3). 
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IV -1.10. N-(SH-dibenzo[ d,f] [1,3]diazepin-6(7H)-ylidene)-3,S-bis(trifluoromethyl) 
aniline (19) 
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Figure IV -17: N-(5H-dibenzo [d,t] [1,3] diazepin-6(7H)-ylidene )-3,5-
bis(trifluoromethyl)aoiline IH-NMR (CDCI3). 
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Figure IV-18: N-(SH-dibenzo[d,t] [1,3]diazepin-6(7H)-ylidene)-3,S-
bis(trifluorometbyl)aniline 13C_NMR (CDCl3). 
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Figure IV-19: (S)-N-(2'-amino-l,1'-binaphthyl-2-yl) acetamide IH-NMR (CDCI3) 
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Figure IV-20: (S)-N-(2'-amino-l,i'-binaphthyl-2-Yl) acetamide 13C-NMR (CDCh). 
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IV -1.12. (S)-N-(2 '-(3-(3,S-his(trifluoromethyl)phenyl)thioureido )-1,1 '-hinaphthyl-2-
yl)acetamide 
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Figure IV -21: (S)-N-(2' -(3-(3,S-bis( trifluoromethyl)pbenyl)tbioureido )-1,1 '-bioapbtbyl-2-
yl)acetamide IH_NMR (CDCh). 
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Figure IV -22: (S)-N-(2 '-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido )-1,1 '-binaphthyl-2-
yl)acetamide 13C_NMR (CDCI3). 
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IV -1.13. (S)-I-( 4-(3,S-his(trifluoromethyl)phenylimino )-4,S-dihydro-3H-
dinaphtho[2,I-d:l ',2'-f] [1,3]diazepin-3-yl)ethanone 
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Figure IV -23: (S)-l-( 4-(3,S-his(trifluoromethyl)phenylimino )-4,S-dihydro-3H-
dinaphtho[2,1-d:l' ,2'-t] [1,3]diazepin-3-yl)ethanone IH-NMR (600MHz, CDCh). 
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Figure IV -24: (S)-l-( 4-(3,5-bis(trit1.uoromethyl)phenylimino )-4,5-dihydro-3H-
dinaphtho[2,1-d:l ',2'-t] [1,3Jdiazepin-3-yl)ethanone 13C_NMR (600MHz, CDCh). 
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IV -1.14. (S)-N-(3H-dinaphtho [2,I-d: 1 ',2 '-f] [1,3]diazepin-4(5H)-ylidene)-3,5-bis 
(trlfluoromethyl)aniline (21) 
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Figure IV -25: (S)-N-(3H-dinaphtho[2,1-d: 1 ',2' -t] [1,3]diazepin-4(5H)-ylidene )-3,5-bis 
(triflnoromethyl)aniline IH-NMR (600MHz, CDCh). 
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Figure IV -26: (S)-N-(3H-dinaphtho [2,1-d: 1 ',2' -t] [1,3]diazepin-4(5H)-ylidene )-3,5-bis 
(trifluoromethyI)aniline 13C-NMR (600MHz, CDCl3). 
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IV -1.15. (R)-1-(2'-amino-[1,1 '-hiphenyIJ-2-yl)-3-(1-«tert-hutyldimethylsilyl)oxy)-3-
phenylpropan-2-yl)thiourea (27) 
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Figure IV -27: (R)-1-(2'-amino-[1,1' -bipbenyl]-2-yl)-3-(1-«tert-butyldimetbylsilyl)oxy)-3-
phenylpropan-2-yl)thiourea IH_NMR (300MHz, DMSO). 
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Figure IV -28: (R)-1-(2'-amino-[1,1 '-biphenyIJ-2-yl)-3-(1-«tert-butyldimethylsilyl)oxy)-3-
phenylpropan-2-yl)thiourea 13C-NMR (300Mllz, CDCh). Double peaks are indicative of 
rotamers. 
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IV -1.16. (R)-I-«tert-butyldimethylsilyl)oxy)-N-(SH-dibenzo [d,f] [1,3]diazepin-6(7H)-
ylidene )-3-phenylpropan-2-amine (28) 
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Figure IV-29: (R)-1-«tert-butyldimethylsilyl)oxy)-N-(5H-dibenzo[d,t] [1,3 Jdiazepin-6(7H)-
ylidene)-3-phenylpropan-2-amine IH_NMR (300MHz, CDCh). 
IV-I.17. (R)-2-«SH-dibenzo[ d,f] [1,3]diazepin-6(7H)-yJidene)amino),·3-
pbenylpropan-I-ol (29) 
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Figure IV -30: (R)-2-«5H-dibenzo [d,t] [1,3Jdiazepin-6(7H)-ylidene )amino )-3-pbenylpropan-
l-ollH-NMR (300MHz, CDCh). 
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Figure IV -31: (R)-2-«5H-dibenzo[ d,t] [1,3Jdiazepin-6(7H)-ylidene )amino )-3-pbenylpropan-
1-ol 13C-NMR (300Mllz, CDCl3). 
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IV -1.18. (R)-2-«Z)-«S)-3H-dinaphtho[2,1-d:1' ,2'-f] [l,3]diazepin-4(5H)-
ylidene )amino )-3-phenylpropan-1-o1 (31) 
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TiJtle- 13.28 
INSTRtn1 spect 
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Figure IV -32: (R)-2-«Z)-«S)-3H-dinaphtho[2,1-d:l' ,2'-t] [1,3]diazepin-4(5H)-
ylidene)amino)-3-phenylpropan-l-ol 1H-NMR (600MHz, CDCI3). 
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NAME PUlBIN 
EXPNO 3 
PROCNO 1 
Da.te 20110105 
T.1.mo- 11 . 32 
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PHOBHD 5 mm PASSO BB-
PUl,PROG zgpg:30 
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t" IDRES 1 .0917 55 Hz 
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Figure IV-33: (R)-2-«Z)-((S)-3H-dinaphtho[2,1-d:l' ,2'-t] [1,3]diazepin-4(5H)-
ylidene)amino)-3-phenylpropan-l-01 13C-NMR (600MHz, CDCh). 
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IV-1.19. (2R)-2-«Z)-(3H-dinaphtho[2,1-d: 1 ',2'-f] [1,3]diazepin-4( 5H)-
ylidene )amino )-3-phenylpropan-l-ol (33) 
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Figure IV -34: (2R)-2-«Z)-(3H -dinaphtho[2,1-d: 1 ',2' -fl [1,3]diazepin-4(5H)-ylidene )amino )-3-
phenylpropan-l-oI1H-NMR (300MHz, CDCI3). 
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Figure IV-3S: (2R)-2-«Z)-(3H-dinaphtho[2,1-d:l' ,2'-t] [1,3Jdiazepin-4(SH)-ylidene )amino )-3-
phenylpropan-l-ol 13C-NMR (300MHz, CDCI3). 
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IV -2. HPLC Information and Spectras for Vinylogous Aldol Adducts 
IV -2.1. 3,4-dichloro-5-«R)-hydroxy(phenyl)methyl)furan-2(5H)-one 
o 
CI 
CI 
HPLC Analysis Chiralpak OD-H (hexanelIPA = 90/10, ImL/min, 254 nm) 17.4 (anti, 
major), 26.2 (antz), 17.1 (syn), 19.1 (syn, major); Using catalyst 29 anti:syn = 62:38; 
35% ee (anti), 49% ee (syn) . Using catalyst 31 anti:syn = 60:40; 12% ee (anti), 16% ee 
(syn). Using catalyst 33 anti:syn = 60:40; 42% ee (anti), 62% ee (syn). 
1~ . 
Figure IV-37: HPLC spectrum of anti isomer for 3,4-dichloro-5-«R)-
bydroxy(pbenyl)metbyl)furan-2(5H)-one using catalyst 29. 
'O!' 
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Figure IV-3S: HPLC spectrum of syn isomer for 3,4-dichloro-S-«R)-
hydroxy(phenyl)methyl)furan-2(SH)-one using catalyst 31. 
mAO. 
Figure IV -39: HPLC spectrum for anti isomer of 3,4-dichloro-S-«R)-
hydroxy(phenyl)methyl)furan-2(SH)-one using catalyst 31. 
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Figure IV-40: HPLC spectrum for syn isomer of3,4-dichloro-S-«R)-
hydroxy(phenyl)methyl)furan-2(SH)-one using catalyst 33. 
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Figure IV-41: HPLC spectrum for anti isomer of3,4-dichloro-S-«R)-
hydroxy(phenyl)methyl)furan-2(SH)-one using catalyst 33. 
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IV -2.2. 3,4-dibromo-5-«R)-hydroxy(pbenyl)metbyl)furan-2(5H)-one 
o 
Br 
HPLC Analysis: anti isomer Chiralpak OD-H (hexanelIP A = 90/10, ImL/min, 254 run) ; 
20.1 (anti, major), 28.2 (anti). Syn isomer HPLC Analysis Chiralpak OD-H (hexanellPA 
= 97/03, 1.2 mL/min, 254 run); 17.1 (syn, major), 19.1 (syn). Using catalyst 29 anti:syn = 
52:48; 37% ee (anti), 61% ee (syn). Using catalyst 33 anti:syn = 50:50; 44% ee (anti), 
64% ee (syn). 
>;IlN{I1- '~;_~o!'iiertni,tth'"2S4 ~m '(PLA1BRS , O) 
nlAO 
'00· 
100 ~ 
Figure IV-42: HPLC spectrum for syn isomer of3,4-dibromo-5-«R)-
hydroxy(phenyl)methyl)furan-2(5H)-one usin2 catalyst 29. 
mAO 
'100 . . 
Figure IV-43: HPLC spectrum for anti isomer of3,4-dichloro-5-«R)-
hydroxy(phenyl)methyl)furan-2(5H)-one using catalyst 29. 
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Figure IV -44: HPLC spectrum for syn isomer of 3,4-dichloro-5-«R)-
bydroxy(pbenyl)metbyl)furan-2(5H)-one using catalyst 33. 
Figure IV-45: HPLC spectrum for anti isomer of3,4-dichloro-5-«R)-
bydroxy(pbenyl)metbyl)furan-2(5H)-one using catalyst 33. 
" 
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IV-2.3. 4-«lR)-(3,4-dibromo-5-oxo-2,5-dihydrofuran-2-yl)(hydroxy)methyl)phenyl 
acetate 
o 
Br 
o 
Br O~ 
HO 
HPLC Analysis Chiralpak OD-H (hexane/IPA = 90110, ImL/min, 254 nm); Using 
catalyst 29 anti:syn = 62:38; 28.3 (anti, major), 40.9 (anti), 28.6 (syn, major), 19.1 (syn); 
17% ee (anti), 55% ee (syn). 
Figure IV -46: HPLC of syn isomer for 4-«lR)-(3,4-dibromo-5-oxo-2,5-dihydrofuran-2-
yl)(hydroxy)methyl)phenyl acetate. 
mAU 
30 . 
. 20 
Figure IV-47: HPLC of anti isomer for 4-«lR)-(3,4-dibromo-5-oxo-2,5-dihydrofuran-2-
yl)(hydroxy)methyl)phenyl acetate 
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IV -2.4. 3,4-dibromo-S-«R)-( 4-bromopbenyl)(bydroxy)metbyl)furan-2(SH)-one 
o 
Br 
Br 
Br 
HO 
HPLC Analysis Chiralpak OD-H (hexane/IPA = 90/10, ImL/min, 254 nm); Using 
catalyst 29 anti:syn = 53:47; 20.7 (anti, major), 29.5 (anti), 17.7 (syn, major), 25.2 (syn); 
51% ee (anti), 51% ee (syn). 
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Figure IV-48: HPLC analysis for syn isomer of3,4-dibromo-5-«R)-(4-
bromophenyl)(hydroxy) methyl)furan-2(5H)-one. 
Figure IV-49: HPLC analysis for anti isomer of3,4-dibromo-5-«R)-(4-
bromophenyl)(hydroxy) methyl)furan-2(5H)-one. 
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IV -2.5. 3,4-dibromo-S-( (R)-(3,S-dimethoxyphenyl)(hydroxy)methyl)furan-2(SH)-one 
o 
Sr 
Sr 
OMe 
HPLC Analysis Chiralpak OD-H (hexanelIPA = 90/10, ImL/min, 254 nm); Using 
catalyst 29 anti:syn = 55:45; 17.3 (anti), 23.0 (anti, major), 24.9 (syn, major), 37.8 (syn); 
35% ee (anti), 65% ee (syn). 
Figure IV-SO: HPLC analysis for syn isomer of3,4-dibromo-S-«R)-(3,S-
dimethoxyphenyl)(hydroxy) methyl)furan-2(SH)-one. 
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Figure IV -S1: HPLC analysis for anti isomer of 3,4-dibromo-S-( (R)-(3,S-
dimethoxyphenyl)(hydroxy) methyl)furan-2(SH)-one. 
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IV -2.6. 3,4-dibromo-5-( (R)-hydroxy( 4-methoxyphenyl)methyl)furan-2(5H)-one 
o 
Br 
Br 
OMe 
HO 
HPLC Analysis Chiralpak OD-H (hexane/IPA = 90/10, ImL/min, 254 nm); Using 
catalyst 29 anti:syn = 51:49; 24.3 (anti, major), 28.7 (anti), 23.1 (syn, major), 28.2 (syn); 
39% ee (anti), 55% ee (syn). 
_,100 
Figure IV-52: HPLC analysis for syn isomer of3,4-dibromo-5-«R)-hydroxy(4-
methoxyphenyl) methyl)furan-2(5H)-one. 
2Q 
Figure IV-53: HPLC analysis for anti isomer of3,4-dibromo-5-«R)-hydroxy(4-
methoxyphenyl) methyl)furan-2(5H)-one. 
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IV-2.7. 3,4-dibromo-5-«R)-hydroxy(4-(trifluoromethyl)phenyl)methyl)furan-2(5H)-
one 
o 
Br 
Br 
CF3 
HO 
HPLC Analysis Chiralpak OD-H (hexane/IPA = 90110, ImL/min, 254 run); Using 
catalyst 29 anti:syn = 46:54; 16.8 (anti, major), 26.1 (anti), 13.3 (syn, major), 19.3 (syn); 
22% ee (anti),53% ee (syn). 
WJ[Ic!A; W.ilv.I"ngtti-2-54rml (PLCPC~)H:' , l 
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Figure IV-54: HPLC analysis for syn isomer of 3,4-dibromo-5-«R)-hydroxy(4-
(triDuoromethyl)phenyl)methyl)furan-2(5H)-one. 
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Figure IV-55: HPLC analysis for anti isomer of 3,4-dibromo-5-«R)-hydroxy(4-
(triDuoromethyl)phenyl)methyl)furan-2(5H)-one. 
IV -2.S. 3,4-dibromo-5-«R)-( 4-chloropbenyl)(bydroxy)metbyl)furan-2(5H)-one 
o 
Br 
Br 
CI 
HO 
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HPLC Analysis Chiralpak OD-H (hexanelIPA = 90110, ImL/min, 254 run); Using 
catalyst 29 anti:syn = 58:42; 16.2 (anti, major), 22.2 (anti), 14.5 (syn, major), 18.5 (syn, 
major); 54% ee (anti), 96% ee (syn). 
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Figure IV-56: HPLC analysis for syn/anti isomers of 3,4-dibromo-5-«R)-(4-
chloropbenyl)(hydroxy) metbyl)furan-2(5B)-one. 
IV -2.9. 3,4-dichloro-S-( (R)-( 4-chlorophenyl)(hydroxy)methyl)furan-2(SH)-one 
o 
CI 
CI 
CI 
HO 
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HPLC Analysis: anti isomer: Chiralpak OD-H (hexane/IPA = 90110, ImL/min, 254 nm); 
Using catalyst 29 anti:syn = 48:52; 14.3 (anti, major), 17.7 (anti); 16% ee. Syn isomer: 
Chiralpak OD-H (hexanelIPA = 95/5, 0.5mL/min, 254nm); 57.3 (syn, major), 64.6 (syn); 
20% ee (syn). 
mAO 
Figure IV-57: HPLC analysis for syn isomers of3,4-dichloro-5-«R)-(4-
chlorophenyl)(hydroxy) methyl)furan-2(5H)-one. 
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Figure IV-58: HPLC analysis for anti isomers of3,4-dichloro-5-«R)-(4-
chlorophenyl)(hydroxy) methyl)furan-2(5H)-one. 
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